Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

12-13-2019

Zoonotic risk of emerging influenza viruses from domestic
animals
Sherry Blackmon

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
Blackmon, Sherry, "Zoonotic risk of emerging influenza viruses from domestic animals" (2019). Theses
and Dissertations. 5044.
https://scholarsjunction.msstate.edu/td/5044

This Dissertation - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

Template C v3.0 (beta): Created by J. Nail 06/2015

Zoonotic risk of emerging influenza viruses from domestic animals

By
TITLE PAGE
Sherry Blackmon

A Dissertation
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy
in Veterinary Medical Sciences
in the College of Veterinary Medicine
Mississippi State, Mississippi
December 2019

Copyright by
COPYRIGHT PAGE
Sherry Blackmon
2019

Zoonotic risk of emerging influenza viruses from domestic animals
By
APPROVAL PAGE
Sherry Blackmon
Approved:
____________________________________
Xiu-Feng (Henry) Wan
(Major Professor)
____________________________________
Larry Hanson
(Major Professor/Graduate Coordinator)
____________________________________
Robert W. Wills
(Committee Member)
____________________________________
Alicia Kathleen Olivier
(Committee Member)
____________________________________
Kent H. Hoblet
Dean
College of Veterinary Medicine

Name: Sherry Blackmon
ABSTRACT
Date of Degree: December 13, 2019
Institution: Mississippi State University
Major Field: Veterinary Medical Sciences
Major Professors: Xiu-Feng (Henry) Wan and Larry Hanson
Title of Study: Zoonotic risk of emerging influenza viruses from domestic animals
Pages in Study: 173
Candidate for Degree of Doctor of Philosophy
Influenza poses a significant global health risk due to the high morbidity and mortality
associated with endemic strains and the pandemic potential of novel strains. This research
characterizes the zoonotic risk of emerging influenza viruses from domestic animals. Chapter
two investigates the genetic compatibility of pandemic H1N1 and emerging canine influenza
H3N2 (CIV-H3N2), first identified in dogs in 2007 and currently responsible for outbreaks in
shelters in the U.S. We generated 51 of the 127 possible reassortant viruses: 19 showed highgrowth phenotypes and 13 replicated in mice lungs. A reassortant with the HA and NP genes
derived from CIV-H3N2 transmitted efficiently by direct contact in ferrets and was more
pathogenic than wild-type CIV-H3N2. Our results suggest that CIV-H3N2 reassortants may pose
a moderate risk to public health and that the canine host should be monitored for emerging
FLUAV. Chapter three is a seroepidemiological study of influenza A (FLUAV) exposure in
shelter dogs in Mississippi, a population not previously investigated. We sampled 565 dogs from
eighteen shelters statewide and identified 7/565 dogs (1.2%) ELISA positive (S/N < 0.70) for
FLUAV exposure but no positive dogs by HI assay. Chapter 4 investigates the pathogenicity of
emerging influenza D virus (FLUDV), first isolated from symptomatic pigs in 2011. Serology
suggests feral swine are exposed to both FLUAV and FLUDV and we investigated whether

coinfection with these two viruses enhances pathogenicity in domestic pigs. In single infections,
5/5 pigs shed FLUAV and 6/7 pigs shed FLUDV in nasal swabs; however, in the FLUAV+
FLUDV coinfection group 7/7 pigs shed FLUAV but only 1/7 shed FLUDV. FLUDV replicated
better in the turbinate and soft palate of single infection group than the coinfection group,
whereas FLUAV replicated equally well in both single and coinfection groups. Our data suggests
coinfection is associated with less robust FLUDV replication in pigs. Collectively, this
dissertation offers insight into emerging influenza viruses originating in dogs and pigs and
potential competitive outcomes associated with coinfection.
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CHAPTER I
INTRODUCTION
One Health Perspectives on Emerging Viruses
Rudolf Virchow (1821-1902), often regarded as the founder of cellular pathology and
comparative medicine, astutely stated, “Between animal and human medicine there are no
dividing lines – nor should there be” and thus emerged the earliest concept of One Health 1-4.
Virchow also defined the term “zoonosis,” a disease transmissible from animals to humans, and
was clearly aware of the unique relationship of zoonotic pathogens and One Health. Since
Virchow’s time, One Health has evolved into a truly global movement, creating a paradigm shift
in our approach to infectious diseases. The One Health Commission, with representatives from
the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food
and Drug Administration (FDA) and United States Department of Agriculture (USDA), defines
One Health as “a collaborative, multisectoral, and trans-disciplinary approach—working at local,
regional, national, and global levels—to achieve optimal health and well-being outcomes
recognizing the interconnections between people, animals, plants and their shared environment”
5

. Other One Health definitions exist; however, their common theme is collaboration,

interdependency and a shared goal to improve health outcomes 6-8.
Zoonotic pathogens pose a substantial global risk to public health and require an
integrated One Health approach for their effective detection, control and mitigation or treatment.
Over 60% of human infectious diseases originate in animals, predominantly from wildlife
1

reservoirs, and over 70% of these zoonotic pathogens are “emerging” 9-12, defined as “a zoonosis
that is newly recognized or newly evolved, or that has occurred previously but shows an increase
in incidence or expansion in geographical, host or vector range” 13,14. Emerging zoonotic
pathogens benefit from a One Health approach and influenza is associated with significant
mortality and morbidity, detrimental economic impacts and pandemic potential. In the Global
Influenza Strategy for 2019-2030, the World Health Organization (WHO) estimates there are one
billion cases of seasonal influenza each year, 3-5 million cases resulting in severe illness and
290,000-650,000 influenza related deaths globally with mortality disproportionately affecting
young children in developing countries 15-17.
Infectious diseases also disproportionately affect low income countries by threatening
food security. Although data is limited, the OIE estimates that approximately 20% of animal
production losses globally are caused by disease 18. Data from sub-Saharan Africa suggest that
around 20% of ruminants and more than 50% of poultry die prematurely each year with 50% of
losses attributed to infectious diseases 19. Although developed countries are food secure, the
economic impacts of transboundary animal diseases are substantial. The 2015 outbreak of
Eurasian origin subtype H5N2 highly pathogenic avian influenza (HPAI) is regarded as the worst
animal health incident in the U.S., resulting in the death of > 50 million birds and economic
losses conservatively estimated at 3.3 billion U.S. dollars within a few months 20-22. Influenza is
a frequent reminder that human and animal health are inextricably linked and a One Health
approach improves health outcomes for all species.
Classification of Influenza Viruses
The International Committee on Taxonomy of Viruses (ICTV) classifies the family
Orthomyxoviridae into seven genera with four genera containing all influenza strains:
2

Alphainfluenzavirus (species: influenza A virus (FLUAV)), Betainfluenzavirus (species:
influenza B virus (FLUBV)) Gammainfluenzavirus (species: influenza C virus (FLUCV)) and
Deltainfluenzavirus (species: Influenza D virus (FLUDV)) 23. Influenza viruses are classified into
species A-D according to genetic and antigenic properties of the nucleoprotein (NP) and matrix 1
(M1) genes 24,25 and on the basis that intratypic, but not intertypic, reassortment of the segmented
genome can occur 25. Only FLUAV is further classified by subtype, based upon the surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA). So far, 18 HA and 11 NA types
have been confirmed, representing 198 theoretical subtypes; however, not all subtypes have been
isolated 26,27. In addition to the ICTV classification system, another useful system was created by
David Baltimore and is based upon genomic nature and mRNA synthesis. Influenza viruses are
classified as Group 5, or negative-sense, single-stranded RNA 28 29. Group five contains
segmented and non-segmented viruses and all influenza viruses have a segmented genome.
Influenza Structure and Genome
Fundamental structural characteristics of influenza viruses have been known as early as
the 1940s, shortly after development of the electron microscope 30. Influenza viruses have an
envelope derived from the host cell plasma membrane and are pleomorphic, either filamentous or
spherical in shape, and 80-120 nm in diameter 31. The morphological variation is primarily
dependent upon the history of the virus: low passage number field isolates are likely to be
filamentous, whereas lab-adapted strains highly passaged in eggs or cell culture are more often
spherical 32-34. The influenza genome consists of negative-sense, single-stranded, segmented
RNA. Segmented genomes are relatively common among RNA viruses and include human,
animal and plant pathogens 35. The distinguishing feature of the segmented genome is the
functional ability to undergo reassortment, or exchange of gene segments, when two viruses
3

infect the same cell. The genomes of FLUAV and FLUBV contain eight viral RNA (vRNA)
segments, whereas FLUCV and FLUDV contain seven vRNA segments. A vRNA gene segment
is protected by multiple copies of nucleoprotein (NP) 50-150 nm in length and attached to a
trimeric viral polymerase complex responsible for replication. This unit is collectively referred to
as a viral nucleoprotein complex (vRNP)

36

.

The FLUAV genome may encode at least 10 or even 14 proteins 36. There are three RNA
polymerase subunit proteins: polymerase basic protein 2 (PB2); polymerase basic protein 1
(PB1); and RNA polymerase acidic protein (PA) that collectively function as a holoenzyme for
replication and transcription of the viral genome 37. Via alternative translation mediated by leaky
ribosomal scanning, the PB1 gene in many FLUAV isolates encodes an auxiliary PB1-F2 peptide
with pro-apoptotic activity 38. There are five structural proteins including NP, matrix proteins 1
and 2 (M1, M2), HA and NA. NP forms the capsid. M1 connects the vRNPs to each other and
with the viral envelope 39, whereas M2 functions as a proton selective viroporin, facilitating the
acidic environment in the late endosome necessary for viral entry and is critical for budding
release of newly formed virions 40,41. HA and NA, in a ratio of approximately four to one, are
critical for viral attachment and release, respectively 42. Nonstructural protein one (NS1) is a
major antagonist of the host innate immune response and especially type I interferon response 43
44

, nonstructural protein two/nuclear export protein (NS2/NEP) mediates the nuclear export of

viral RNAs 45. FLUBV encodes at least 11 proteins, nine of which are also encoded by FLUAV
as discussed above; however, instead of M2, FLUBV encodes NB and BM2 46 and it does not
encode PB1-F2 47. FLUCV and FLUDV encode at least nine proteins. A significant difference
shared by FLUCV and FLUDV is the hemagglutinin-esterase-fusion (HEF) surface glycoprotein
that catalyzes receptor binding, cleavage, and membrane fusion 48-50. HEF is functionally like
4

HA and NA proteins encoded by FLUAV and FLUBV; however, it is structurally unique. It will
be discussed in greater detail in the section on emerging FLUDV.
Influenza Infection Cycle
The influenza virus infection cycle is initiated by attachment of viral glycoprotein HA
(FLUAV/FLUBV) or HEF (FLUCV/FLUDV) to host cell sialic acid receptors typically located
in the nose, trachea and lungs of mammals. Following attachment, the majority of influenza
viruses enter the cell via clathrin coated pit endocytosis 24, although perhaps as many as 30%
may rely on clathrin-independent mechanisms for internalization 51. A low pH of the endosome,
facilitated by viral M2 protein, triggers a conformational change in HA0. HA0 must be cleaved
by host proteases into subunits HA1 and HA2 to undergo the conformational change that leads to
fusion of the viral and endosomal membranes, thus allowing “escape” of the vRNPs into the
cytoplasm. The vRNPs are trafficked into the nucleus where primary transcription of mRNAs by
viral RNA polymerase is primed by “cap snatching” of the 5’ ends of host pre-mRNAs 24,36. By
using primers, viral mRNA transcription is more efficient and abundant than the viral genome
replication during the early stage of infection. The primary transcript mRNA is exported to the
cytoplasm and translated into protein by host ribosomes. After translation, proteins are either
transported back to the nucleus for assistance in genome replication of vRNPs or to the plasma
membrane 36. The M1 and NS2/NEP proteins assist in exporting the progeny vRNPs to the
cytoplasm where they are trafficked to the plasma membrane on Rab11 vesicles and assembled
into progeny virus particles 36. At the host cell membrane, the virion is packaged in a 7+1
configuration regardless of whether the strain has eight gene segments (i.e. FLUAV/FLUBV) or
seven gene segments (i.e. FLUCV/FLUDV) 52,53; however, it’s unclear whether the 7+1
configuration predominates after budding 54, the last step in the infection cycle. Budding from
5

the plasma membrane is mediated by at least two viral proteins: M2 promotes curvature
necessary for budding and membrane scission while NA prevents aggregation by cleaving host
sialic acids as budding occurs 36,55,56. The entire infection cycle can be completed in
approximately one hour 57.
Mechanisms of Viral Diversity and Evolution
Mutation and Antigenic Drift
The epidemiological success of influenza viruses results from antigenic variation via
mechanisms of mutation and reassortment. Compared to DNA viruses, RNA viruses have an
increased mutation frequency due to their low-fidelity, “error-prone” RNA-dependent RNA
polymerase (RdRp) (i.e. lacking the 3’ → 5’ exonuclease proofreading capability of DNA
polymerase). A metanalysis of over 40 studies estimated a mutation rate ranging from 10−8 to
10−6 for DNA viruses and 10−6 and 10−4 substitutions per nucleotide site per cell infection (s/n/c)
or round of copying (s/n/r) for RNA viruses and relied upon a statistical method to minimize the
selection bias of deleterious mutations 58. Although the outcome of most random mutations is
detrimental or lethal, nondeleterious mutations may be preserved and subsequently amplified in
the population if they confer a fitness advantage 59. High mutation frequency and within-host
selective pressure creates quasispecies, defined as a proliferating population of non-identical but
closely related viral genomes 60.
The mutations of FLUAV accumulate predominantly in the antigenic sites of the surface
glycoproteins HA and NA. However, overall mutation and substitution frequency is a complex
association of factors that are genus, strain and gene specific; environmentally influenced (i.e.
temperature, pH, etc.) and subject to within-and between-host immune selection pressure and
results in variable evolutionary rates 61. Influenza evolution resulting in accumulated mutations is
6

referred to as “antigenic drift” and is responsible for seasonal influenza epidemics that
necessitate annual vaccine formulations. To account for antigenic drift, the vaccine composition
is revised almost yearly and separately in both the Northern and Southern Hemispheres and
incorporates contemporary representatives of circulating viruses identified by continuous global
monitoring and surveillance by WHO’s Global Influenza Surveillance and Response System 62.
Genome Restructuring and Antigenic Shift
Unlike mutations, reassortment results in restructuring the genome. Reassortment occurs
if two strains from a shared genus infect the same host cell and produce a novel viral genotype,
i.e. an assembly of segments from each “parental” strain. Reassortment has been demonstrated
for FLUAV, FLUBV, FLUCV and FLUDV 25,63-66. As is the case of random mutations, most
reassortant events are deleterious, usually due to segment incompatibility 67. When reassortment
leads to the introduction of a novel HA and/or a NA gene into a naive population, i.e. typically a
population without any existing immunity, it is commonly referred to as “antigenic shift” 68.
Antigenic shift in combination with sustained human-to-human transmission are necessary
requirements for influenza pandemics. Reassortment led to the emergence of the 1957, 1968, and
2009 FLUAV pandemics and contributed to the severe epidemics of 1947, 1951 and 2003 and
rise in antiviral drug resistance 69.
Another source of genetic diversity is homologous and nonhomologous recombination,
but this is rare or absent in FLUAV, although the term “recombination” may be a source of
confusion when used to describe the outcome of reassortment which is common for FLUAV.
Recombination occurs when short regions of sequences are transferred by the process of
polymerase complex copy choice or template-switching and may occur in coinfected cells 70.
Homologous and non-homologous recombination frequency varies significantly among different
7

viruses; however, both are considered rare among negative-strand RNA viruses in general and
very rare or absent in human FLUAV 70-75. In one review of 13,852 full-length sequences from
human H1 and H3 FLUAV strains, only 315 sequences (~2%) from five gene segments showed
mosaic signals compatible with homologous recombination and only two were >100 nucleotides
70

. There is considerable challenge in distinguishing potential homologous recombination events

from lab-generated errors in sequencing. In a follow-up study of 8,307 full-length sequences
submitted exclusively by the National Institutes of Health Influenza Genome Sequencing Project
under rigorous quality control, only two possible recombinant events were identified 75.
Sialic Acid Receptors and Host Tropism
Sialic acids, nine carbon glycans with over 50 unique structures identified to date, are
important contributors to the host glycome and modulate diverse physiological and pathological
processes 76-81. Many pathogenic fungi, protozoa, bacterial and viral families recognize sialic
acids. Viral families with at least one representative strain binding a sialic acid receptor include
orthomyxo, paramyxo, corona, reo, polyoma, adeno, picorno, parvo, papilloma, herpes, rhabdo,
and hepdna 82. Sialic acid receptor structure and distribution determines host cell susceptibility
and is therefore a major determinant of host range and pathogenicity of influenza 83. Receptors
for influenza are located on epithelial and goblet cells and mucins in the mammalian respiratory
tract and avian respiratory and gastrointestinal tracts.
Influenza may bind at least three known classes of sialic acid receptors. FLUAV viruses
predominantly bind terminal N-acetylneuraminic acid (Neu5Ac) sialic acid receptors, but can
also bind N-glycolylneuraminic acid (Neu5Gc) 81. Neu5Gc is expressed in pigs and horses and
other mammals, but not endogenously expressed in humans, ferrets, seals, or dogs as these
species lack the enzyme, cytidinemonophosphate-N-acetyl neuraminic acid hydroxylase
8

(CMAH) , that converts Neu5Ac to Neu5Gc 77,84. In species lacking CMAH, Neu5Gc specificity
represents a FLUAV species barrier. Equine H7N7 was the last known circulating Neu5Gc strain
and hasn’t been isolated since the 1970s 85. A third class of sialic acid receptors, Neu5Ac
modified with O-linked acetyl groups at carbon -9 (Neu5,9Ac2), are utilized by FLUCV and
FLUDV 25,86,87.
Evidence suggests FLUDV may have broader host cell tropism than FLUCV due to a
difference in the structure of the HEF protein at the receptor-binding site. Specifically, between
the 230-helix and 270-loop within the receptor-binding pocket, FLUCV HEF forms a salt bridge
between cationic K235 and anionic D269, thus creating a closed channel, whereas the FLUDV
HEF sequence is T239 and A273, cannot form ionic attraction, and the result is an open channel
that theoretically may accommodate diverse extended glycan moieties 88. The broader cellular
tropism of FLUDV may be one reason more species are susceptible to FLUDV than to FLUCV
which has only been identified in humans and swine 49. Glycan array data showed that the HEF
protein of FLUDV can bind both Neu5Ac and Neu5Gc sialic acids carrying a 9-O-acetyl group
87,88

.
Human FLUAV viruses preferentially bind Neu5Ac receptors with an α2,6 linkage to the

penultimate galactose; avian and equine FLUAV have a greater affinity for α2,3 linkages 89-93,
whereas some swine viruses bind well to both α2,6 and α2,3 linkages. The α2,3 linkage is
frequently described as having a “cone” topology with less conformational flexibility compared
to the α2,6 “umbrella” shape with increased structural flexibility 79,94,95. Specific amino acid
substitutions that shift receptor binding affinity from α2,3 to α2,6 sialic acids increase human
susceptibility because the distribution of α2,6 receptors throughout the human respiratory tract is
more abundant than α2,3 receptors, although both types are present. However, increased affinity
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for α2,6 sialic receptors, alone, may not result in FLUAV host switch from avian to human. For
example, H7N2, H7N3 and H9N2 show enhanced affinity for α2,6 receptors but have only
caused sporadic human disease 96. Furthermore, avian viruses that preferentially bind α2,3
receptors can infect humans, especially if the exposure dose is large or makes contact with the
conjunctiva or lower respiratory tract including bronchi and alveoli where α2,3 expression is
greatest 77.
Pathogenesis of FLUAV viruses
Virus genes and host factors that increase pathogenicity are complex, multifactorial traits.
Factors that determine influenza pathogenicity may be classified in terms of their impact on
cellular and tissue tropism, spread of infection, virus load, evasion of host defenses, modulation
of inflammatory response and synergistic bacterial infection, to be discussed in the last section
on mixed infections

97,98

. Strains with mixed affinity for α2,3 and α2,6 receptors may increase

pathogenicity in humans because there are more α2,3 receptors in the deep lower respiratory tract
where disease may be more severe, especially if it leads to a secondary bacterial infection. For
example, the amino acid substitution from aspartic acid to glycine at position 222 (D222G) in the
HA1 protein of some 2009 pH1N1 strains is associated with severe disease and higher case
fatality rate

99,100

. The D222G mutation is associated with a shift in receptor binding from

predominantly α2,6 to mixed α2,3/α2,6 and infection in the lower respiratory tract targets ciliated
bronchial cells, macrophages and type II pneumocytes in the alveoli 101-103. However, although
replication in the lower respiratory tract may be associated with enhanced pathogenicity,
enhanced replication in the upper respiratory tract is associated with improved transmission.
A well categorized virulence factor that enhances virus dissemination and systemic infection
is a multibasic cleavage site in the HA0 protein of HPAI. The HA0 protein requires cleavage into
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HA1 and HA2 to become infectious 104. The HA0 monobasic site is restricted to cleavage by
serine proteases secreted by nonciliated epithelial cells, localized to the gastrointestinal and
respiratory tract in birds and humans, respectively. LPAI and most seasonal human influenzas
have a monobasic amino acid, usually arginine, at the HA0 cleavage site; however, HPAI can
use ubiquitous host proteases, e.g. furin in the trans-Golgi network, resulting in severe, systemic
disease 105-107. However, although evidence suggests that a multibasic HA0 cleavage site is
necessary, it may not be sufficient to confer virulence in avian hosts as demonstrated in an
animal study using 4-week-old White Leghorn specific pathogen–free (SPF) chickens 108 and its
role is even less clear in mammalian hosts such as mice 105. Pathogenicity caused by even well
characterized virulence factors is very much host dependent.
Virus load is one measure of disease severity in animal models and is determined partly by
the efficiency of the RdRp complex, thus making it a major determinant of host specificity and
pathogenicity. Position 627 of PB2 is usually glutamic acid (E) in avian viruses or lysine (K) in
mammalian strains. Subbarao et al showed that a single substitution in PB2 at position 627
(Glu→ Lys) allowed a 7+1 human reassortant to replicate in mammalian MDCK cells whereas
627E could not, suggesting PB2 is a significant determinant of host range 109. Mutation at PB2
627 is also recognized to increase replication efficiency and pathogenicity in mice and ferrets
110,111

. Bussey et al demonstrated even greater pathogenicity in mice infected with a PB2 T271A

+ E627K double mutant 112. These mice had enhanced lung pathology including severe
inflammatory cell infiltration around blood vessels and in the lung parenchyma leading to
hemorrhage and alveolar destruction 112. Polymerase activity is increased significantly with PB2
627K and 271A in mammalian 293T cells relative to wild-type PB2. These findings may partly
explain the pathogenicity of the pandemic A/California/04/2009 (H1N1) with its avian-origin
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PB2 271A mutation 112. RdRp mutations may also increase pathogenicity via interactions with
host factors independent of increasing the viral polymerase activity. Gabriel et al showed that
PB2 mutation D701N and NP mutation N319K enhance binding to importin α1, a component of
the nuclear pore complex, in mammalian but not avian cells 113.
Influenza evasion of host defenses is further categorized by strategies to escape the host
innate and adaptive immune response. Antigenic shift and antigenic drift, previously discussed
above, are the primary strategies of escape from the adaptive immune system. However, posttranslational modification of glycosylation moieties of the HA and NA protein can also result in
antigenic change. Pathogen-associated molecular properties, for example terminal mannose
residues found in influenza HA and NA proteins that are not typically present in human
glycoproteins, are recognized by the innate immune system which activates pattern recognition
receptors that ultimately limit viral replication, recruit more innate immune cells, eventually
leading to an adaptive immune response 114. Viruses with low levels of glycosylation including
the pandemics of 1918 H1N1, 1957 H2N2, 1968 H3N2 and 2009 H1N1 are generally more
resistant to neutralization by host innate defenses, including collectins surfactant protein D and
mannose-binding lectin, whereas highly glycosylated viruses are more susceptible 114. Altman et
al. recently showed a temporal pattern of HA protein glycosylation for H1 and H3 viruses that
adds a new glycan every 5-7 years until reaching a functional glycan limit, followed by
replacement with a minimally glycosylated HA from an animal reservoir 115.
In addition to glycosylation of HA and NA proteins, the NS1 protein can also antagonize the
host innate immune response and promotes pathogenesis. Generation of mutant FLUAV lacking
the NS1 gene attenuates PR8 influenza infection in MDCK cells and in mice, but not in Vero
cells which lack an interferon response, by allowing a robust interferon upregulation that inhibits
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viral replication 116. One mechanism for NS1 antagonism of the host innate immune response is
via inhibiting TRIM25 ubiquitination which is required for activation of retinoic acid-inducible
gene I (RIG-1) mediated interferon production 117. The RIG-1 pathway, essential in epithelial
cell interferon induction, is induced by preferentially binding viral RNA, i.e. has a greater
affinity for ssRNA without 5′OH or 5′-methylguanosine cap 118. Modulating the innate immune
response via interferon inhibition often enhances virus production, but the host may also respond
to infection with a robust interferon response. If the response is too robust, this may lead to a
“cytokine storm” characterized by overproduction of interferon leading to upregulation of
additional proinflammatory cytokines, excessive infiltration of the tissue by immune cells
leading to tissue destruction. Production of a cytokine storm was a key feature of the 1918
pandemic 119 with a robust immune response contributing to the unusual “W” shaped mortality
pattern, i.e. the 25-34 year old age group had the second highest mortality after the very young
and very old 120. A more typical FLUAV mortality pattern is “V” shaped with the very young
and very old most susceptible.
Apoptosis, or programmed cell death in the absence of inflammation, is an energydependent, caspase-mediated biochemical mechanism characterized by morphological features
including cytoplasmic and nuclear condensation, chromatin cleavage, apoptotic bodies,
maintenance of an intact plasma membrane, and exposure of surface molecules targeting
phagocytosis and efficient removal of the cell and its contents 121-124. FLUAV and FLUAB, like
other viral pathogens, induce apoptosis in vitro and in vivo but the mechanisms are not well
understood and likely strain, host and cell type specific. Activation or prevention of apoptosis
may be proviral, antiviral or both depending on the time course of infection 125. Cleaved-caspase
3 is an early indicator of apoptosis and frequently considered an antiviral host defense
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mechanism, but its activation is essential for efficient FLUAV replication, suggesting a temporal
balance of pro-apoptotic and anti-apoptotic activity is required 126. NS1 protein induces an
interferon response that is a critical temporal component of apoptosis, but the interferon response
is host specific. PB1-F2 in human and avian, but not swine, enhances pathogenicity by inducing
apoptosis via a mitochondrial membrane permeabilization pathway in some FLUAV strains but
not others 47,127,128 and/or potentiating the inflammatory response to the virus itself, co-infecting
bacteria or both 129,130.
Reservoirs, natural hosts and ecology of FLUAV
The complex and dynamic interspecies transfer of FLUAV poses the greatest risk to
public health and is the focus of most research of influenza ecology. FLUAV was first isolated
from aquatic birds in 1961 131 and to date, all 16 HA and 9 NA subtypes have been identified in
aquatic birds, primarily Anseriformes (i.e. ducks, geese, and swans) and Charadriiformes (i.e.
gulls, terns and waders) 132. These wetland and aquatic birds are the reservoirs for FLUAV and
original source for all mammalian FLUAV 63. Additional subtypes, H17 and H18 and NA 10 and
11, that have been identified in bats; however, the HA and NA proteins of bat influenzas appear
to function differently than avian and mammalian FLUAV 26,27. Many hosts are susceptible to
FLUAV infection including terrestrial poultry, humans 59,133, pigs 134, horses 135, dogs 136,137, cats
138

, mink and ferrets, seals 139 and whales 140.

Human influenza
Human influenza related morbidity and mortality can be broadly classified by pandemics
and interpandemic (endemic) periods. At least 14 FLUAV pandemics may have occurred since
1500 with interpandemic periods averaging 40 years 141. The last four documented pandemics
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include the 1918 “Spanish” flu (H1N1) and lesser pandemics of 1957 (H2N2), 1968 (H3N2), and
2009 (H1N1) 141. The 1918 influenza is estimated to have caused 675,000 deaths in the United
States and 50 million deaths worldwide 142,143, a vast figure that researchers acknowledge may be
understated by 100 percent 144.
Interpandemic periods are also referred to as “seasonal influenza” and refer to FLUAV
(subtypes H1 and H3 and N1 and N2) and FLUBV. “Spillover” infections occur outside of the
H1 and H3 subtypes, but these are incapable of sustained human-to-human transmission. The
WHO estimates there are one billion cases of seasonal influenza each year and 3-5 million cases
resulting in severe illness and 290,000-650,000 influenza related deaths globally 15-17. In 2003,
the total economic burden of seasonal influenza in the U.S. was estimated at $87.1 billion USD
143,145

. The primary method for preventing seasonal influenza is via annual vaccination; however,

many challenges exist. First, matching the vaccine composition to circulating strains is difficult
due to antigenic drift as discussed in the previous section on virus evolution. For example, the
vaccine virus strains included in the 2018-19 U.S. trivalent influenza vaccines are
A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Singapore/INFIMH-16-0019/2016 (H3N2)like virus and a B/Colorado/06/2017-like virus (Victoria lineage), whereas quadrivalent
influenza vaccines will contain an additional influenza B vaccine virus, a B/Phuket/3073/2013like virus (Yamagata lineage) 146. Another challenge is that vaccination compliance is less than
ideal. Healthy adults who don’t perceive a substantial risk associated with seasonal influenza
forego vaccination, but are still susceptible, and more likely to be asymptomatic spreaders to
more vulnerable populations. Even when the vaccine is well matched and compliance is
successful, the immune system response in certain populations including the young,
immunocompromised and the elderly may be insufficient. Finally, evidence also suggests that
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waning intraseasonal immunity is a significant challenge, suggesting that people vaccinated very
early in the influenza season may not be adequately protected in the later part of the season 147.
Swine influenza
Swine-FLUAV (Sw-FLUAV) causes economic burden, negatively impacts animal
welfare and poses a threat to public health due to its zoonotic risk and complex ecology. In pigs,
lethargy and failure to gain are economic factors even in uncomplicated influenza where herd
mortality is usually less than 1% but morbidity may approach 100%

148

, thus ranking swine-

FLUAV as one of the top three health challenges facing the swine industry 149. Classical swine
H1N1 (cH1N1) was recognized in the North American pig population during the timeframe of
the 1918 H1N1 pandemic 150,151 but not distinguished as a viral etiology until 1931 by Shope
who isolated the virus from symptomatic pigs 134,152. Sw-FLUAV was the first mammalian
influenza to be isolated, occurring about two years earlier than viral isolation from symptomatic
human patients 133. For approximately 80 years, cH1N1 remained genetically stable and was the
predominant circulating subtype until the 1998 enzootic event of H3N2 was identified in pig
herds in four U.S. states 153,154. This H3N2 was characterized by a double or triple reassortant
internal gene (TRIG) cassette and by the end of 1999, the triple reassortant that contained human
(HA, NA, PB1), swine (NS, NP, M), and avian (PB2, PA) genes was widespread 155.
Presently, the swine industry faces challenges due to the antigenic drift of H1 and H3 SwFLUAV, but especially the H3 subtypes 155-158. Swine surveillance is not as robust as
surveillance of human strains and the vaccine composition may not match circulating strains in
the geographic region the vaccine is used. In high income countries that rely upon animal
vaccines, regulatory hurdles may hinder rapid vaccine reformulation when it’s needed, whereas
middle to lower income countries would benefit from enhanced regulations and improved
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availability and affordability of vaccines. Another challenge in the control of Sw-FLUAV is the
enormous feral swine population susceptible to FLUAV. In 2018, the U.S. feral swine population
was estimated to be 6 million and increasing and has been reported in 35 states 159. Most
zoonotic diseases emerge from wildlife reservoirs and feral swine transmit diverse pathogens,
including FLUAV, to domesticated swine. Serological studies showed feral swine were
previously exposed to avian and swine influenza strains 157, providing the opportunity for the
them to serve as “mixing vessels” for potential reassortant events.
Pigs were first described as “mixing vessels” by Scholtissek in 1985 160; however, the
2009 pandemic H1N1 (pH1N1) increased the public awareness of the zoonotic risk of influenza.
The pH1N1 contained 6 segments from the swine TRIG cassette and two segments (NA and M)
from Eurasian avian-like swine lineage.
Pigs are considered “mixing vessels” because their epithelial cells in the respiratory tract express
both α2,3 (“avian type”) and α2,6 (“human/swine type”) receptors and avian subtypes H1-H13
are capable of prolonged replication in pigs 161-163. Because they can serve as mixing vessels and
have a large global population, pigs increase the likelihood of introducing novel strains into the
human population that may result in sustained human-to-human transmission. Additionally, pigs
are highly susceptible to reverse zoonotic disease transmission. These strains spread from
humans to pigs where they undergo genetic drift and/or shift before being transmitted back to
humans as variant viruses. The 2011 H3N2 variant cases were of special concern because
person-to-person transmission was suspected 164,165.
Sw-FLUAV presents challenges to the swine industry and public health due to the high
antigenic diversity and geographic specificity of circulating strains, creating a barrier to effective
and cost-efficient vaccines. FLUAV swine surveillance is lacking in many regions of the world.
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In lower income countries, limited resources are allocated to pig pathogens of greater economic
impact. However, even in upper-middle income countries biosecurity systems are less than ideal.
China is the world’s largest producer and consumer of pork, producing almost 50% of global
supply and yet, the recent African Swine Fever outbreak has decimated China’s pig production,
partly due to the low-biosecurity of small-scale and backyard farms that produce more than 60%
of China’s pigs 166.
Equine influenza
In addition to humans and pigs, horses have long been recognized as a natural host for
sustained influenza transmission. Evidence suggests influenza epizootics in horses in 1299 in
Europe and 1328 in Yemen that coincide with suspected human influenza outbreaks 167. A welldocumented equine influenza outbreak occurred in the U.S. in 1872 when transportation, travel,
and delivery of mail and other goods ceased for weeks, also coinciding with a suspected human
influenza outbreak 167,168. Two FLUAV subtypes have been identified in horses including H7N7
and H3N8, identified in 1956 and 1963, respectively 167,169. H7N7 has not been isolated since the
1970s; however, avian-origin H3N8 continues to circulate and diverge. Equine H3N8 is
considered endemic in most regions of the world, although surveillance outside of high resource
countries is extremely limited. Influenza is one of the most common respiratory diseases in
horses and although not classified as a core vaccine by the American Association of Equine
Practitioners (AAEP), horses in the U.S. are frequently vaccinated. In 2018 the OIE
recommended vaccination for horses traveling internationally with a vaccine containing
representative strains from Clade 1 (e.g. A/South Africa/2003-like or A/Ohio/2003-like) and
Clade 2 (A/Richmond/2007), recommendations that have not changed since 2010 170. Equine
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influenza H3N8 infects dogs and has also been isolated from a camel 171, and donkeys 172 and
pigs in China 173.
Canine influenza
Unlike humans, pigs and horses, dogs have a relatively short history of sustained influenza
transmission. Equine-origin H3N8 (CIV-H3N8) and avian-origin H3N2 (CIV-H3N2) are the two
enzootic subtypes in the canine population. CIV-H3N8 was identified in 2004 in Florida, United
States, as a result of a severe respiratory disease outbreak at a racing track shared by greyhound
racing dogs and horses 137. However, a retroactive serological study suggested infection as early
as 1999 with antibodies to CIV and EIV H3 proteins detected in 133/520 (26%) of racing
greyhounds 174. CIV-H3N8 has also been retrospectively detected in English foxhounds exposed
to an equine influenza outbreak in 2002 in the U.K. 175 and in multiple dog breeds in Australia
during a 2007 equine influenza outbreak 176. However, only in the U.S. was there sustained
transmission of CIV-H3N8. Amino acid substitutions were present in the earliest isolate of CIVH3N8 in Florida that were not detected in isolates from the U.K. or Australia where the sequence
homology was identical to equine H3N8.
In the U.S., CIV-H3N8 spread across the country with high levels in 2005 until it was mostly
undetected by 2014. Anderson et al. collected sera (years 2005 – 2009) from shelter and owned
animals (n=1,268) from 42 states with influenza-like illness and determined the overall
seroprevalence of CIV-H3N8 was 49% 177. In a small study within the same timeframe (sera
collected Oct-Dec 2008), Holt et al. collected sera from 74 dogs at a metropolitan animal shelter
in Philadelphia, Pennsylvania and determined seroprevalence of CIV-H3N8 42% 178. Pecoraro et
al. collected sera from shelter dogs (n=5,160) during years 2009 – 2012 and by this time
seroprevalence of CIV-H3N8 was decreasing across the U.S. with 10% seroprevalence in
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Colorado, 8.5% in New York and 0% in South Carolina, Florida, California, Texas 179. Jang et al.
obtained sera from pet dogs (n=1,082) presenting to Ohio State College of Veterinary Medicine
for preventative care and elective surgery from 2012 – 2014 and showed seroprevalence of CIVH3N8 was a very low 2.3% 180. Seroprevalence was higher against human H1N1 at 4% and
H3N2 at 2.4% 181. Collectively these studies suggest CIV-H3N8 currently circulates at very low
levels and mostly within shelter populations in urban regions 182.
Avian-origin canine influenza H3N2 (CIV-H3N2) was first identified in 2006 in Korea and
China and later detected in Thailand and other areas of Southeast Asia 183-189. It was
hypothesized that transmission occurred in a live market where farmed dogs were housed in
close proximity to avian species because seroprevalence was as high as 100% in some farmed
dog populations 188. The first CIV-H3N2 epizootic outside of Asia occurred in the Chicago area
of the U.S. in late February 2015. It was characterized by mild to moderate respiratory disease
and low mortality that affected over 1000 dogs and spread to 23 additional states within 5
months 190. It may also have originated from farmed dogs, perhaps by their rescue and import
into the U.S. by animal welfare organizations 191. Serological evidence suggests CIV-H3N2, like
CIV-H3N8, currently circulates at very low levels in the U.S. Gutman et al. retrospectively
obtained sera (n=451) collected April – August 2015 at Purdue University Veterinary Hospital
and seroprevalence was 2.21% by HI assay against CIV-H3N2 192. These results are informative
as this was the time period and general location of the outbreak. Evidence suggests there have
been at least two additional introductions of CIV-H3N2 in the U.S. from Asia, including an early
2017 outbreak in Los Angeles traced to dogs imported from China and an outbreak in the
Southeastern U.S. in May 2017 that likely originated from Korea 193.
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Dogs warrant special consideration as influenza hosts for several reasons, including that
they are susceptible to avian and mammalian FLUAVs and, as is the case with swine, may act as
“mixing vessels” for creating reassortant viruses 194-196. Both α2,3 and α2,6 sialic acid receptors
have been identified in the canine respiratory tract, although predominantly α2,3 87,175,197,198.
Dogs also have a large global population with a recent estimate ~700 million 199 and unlike pigs,
dogs have close physical contact with humans, often sharing the family home in Western
countries. Dogs also have close contact with other dogs, a necessary factor for transmission. In
many developing countries free-range dogs roam and interact and in developed countries, large
dog populations are housed in shelters. In China cultural attitudes toward dog ownership are
becoming more Westernized 200.
Dogs have been infected with many influenza strains, including avian strains H5N1 201,
H5N2 202, H9N2 203, and H10N8 204. Serological evidence as early as the 1970s suggests dogs
can be infected with human strains of H1N1 and H3N2 136,205 and more recent evidence also
shows dogs seropositive for seasonal H3N2 and pdmH1N1 180,206,207. In China, more than 20% of
domestic dogs have serum antibodies for pdmH1N1 and dogs positive for both CIV-H3N2 and
pdmH1N1 have been identified 187,208. In 2012, a virus isolate containing the HA gene from CIVH3N2 and the remaining seven genes from pdmH1N1 was identified 209 and another isolate
contained the M gene from pdmH1N1 and all other genes from CIV-H3N2 210. Reassortants of
CIV-H3N2 x SwFLUAV (H1N1) have also been isolated and phylogenetic analysis suggests
sustained transmission in dogs 200. Although CIV-H3N2 has mostly reassorted with other
mammalian influenzas, an avian-origin reassortant with a PA gene from avian-origin H9N2 was
identified in 2015 211. Although the viral genetic diversity in pigs exceeds the relatively stable
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lineages in dogs, the public health implications of influenza in dogs necessitates continued
surveillance of this unique host.
Emerging FLUDV
FLUDV, the most recently identified influenza species, was first isolated in 2011 from
pigs showing signs of respiratory disease 49. FLUDV shares approximately 50% homology with
FLUCV, similar to the shared homology between FLUAV and FLUBV, and FLUDV does not
cross-react with FLUCV antibodies or reassort with FLUCV, and on this basis is classified as a
separate genus

25,49

. Data show FLUDV is transmitted by direct contact in bovids 212, ferrets 49,

domestic pigs 49 and guinea pigs 213. In nature, FLUDV has been identified in bovids, 25, small
ruminants, 214, camels 215 and horses 216, indicating it has a diverse host range similar to FLUAV.
FLUDV appears to be globally widespread and has been isolated and/or identified by serology in
Mexico 217; Italy 218,219, France 220, Ireland 221 and Luxembourg 222; China 223,224 and Japan 225;
and Kenya, Morocco, Togo and Benin 215. Because some studies have estimated seroprevalence
in bovids as high as 80%, bovids are the suspected reservoir of FLUDV 222. Seroepidemiological
studies in domestic swine have estimated prevalence at 9.5% 49 and 11.7% 218. A study in our lab
estimated an approximately 19.1% seroprevalence in feral swine and their potential interaction
with domestic pigs and cattle further complicate the ecology of FLUDV 226.
Data suggests infection with FLUDV causes mild pathogenicity in cattle 212 and may be
associated with coinfections. FLUDV has been associated with bovine respiratory disease (BRD)
complex, a disease of significant economic burden even in high income countries. BRD is
frequently a mixed infection of viral and bacterial pathogens, including bovine viral diarrhea
virus, infectious bovine rhinotracheitis virus, bovine respiratory syncytial virus and/or
parainfluenza type 3 and bacteria Mannheimia haemolytica, Pasteurella multocida, Histophilus
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somni, and/or Mycoplasma bovis. One study showed 18% (8/45) of cows with respiratory disease
were RT-PCR positive for FLUDV 25. Another study showed 5% (10/208) were RT-PCR
positive for FLUDV, including one sample positive for both FLUDV and bovine viral diarrhea
virus and four samples positive for FLUDV and bovine coronavirus 227. Metagenomic
characterizations in one study of dairy cattle showed an association between FLUDV and BRD
228

but FLUDV was also identified in dairy cows without BRD symptoms. Another study in beef

cattle showed 99% of the FLUDV reads were derived from BRD symptomatic animals,
suggesting FLUDV may be associated with BRD 217. However, a previous study in our lab didn’t
show FLUDV and Mannheimia haemolytica coinfected cattle to have worse clinical scores or
lung pathology than animals infected with only Mannheimia haemolytica 229.
Because FLUDV has so recently been identified, the public health implications of
FLUDV remain unknown. One small study showed cattle workers approaching 100%
seroprevalence of FLUDV compared to the general population 230, however a large study
(n=3300 general population, Scotland) detected no FLUDV 231. Data suggests the FLUDV HEF
protein can also bind human trachea epithelial cells and may pose a threat to human health 88.
Evidence suggests FLUDV may have broader host cell tropism than FLUCV due to a difference
in the structure of the HEF protein at the receptor-binding site. Specifically, between the 230helix and 270-loop within the receptor-binding pocket, FLUCV HEF forms a salt bridge between
cationic K235 and anionic D269, thus creating a closed channel, whereas the FLUDV HEF
sequence is T239 and A273, cannot form ionic attraction, and the result is an open channel that
theoretically may accommodate diverse extended glycan moieties 88.
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Mixed Infections
The respiratory tract microbiome is a dynamic ecosystem of commensal, opportunistic
and pathogenic microorganisms. Respiratory disease complex (RDC) is a multifactorial disease
in cattle, pigs, dogs, humans and other hosts although the role of coinfection is unclear. The
general pattern of viral-bacterial relationships is often recognized as either having no effect or as
synergistic, i.e. influenza facilitates bacterial infection, whereas viral-viral pathogens tend to
form competitive or antagonistic interactions 232. FLUDV may play a role in multifactorial BRD
as discussed above. Other examples include swine influenza viruses that recognize the α2,6 sialic
acids in the capsule of Streptococcus suis and both are significant contributors to porcine
respiratory disease complex 233. Canine infectious respiratory disease or “kennel cough” was
classically associated with infection by Bordetella bronchiseptica, often in conjunction with or
preceded by canine parainfluenza virus, canine adenovirus type 2 or canine herpesvirus 1.
However, novel or reemerging pathogens have also been identified including canine respiratory
coronavirus, canine pneumovirus, canine influenza virus, pantropic canine coronavirus,
Streptococcus zooepidemicus, and Mycoplasma cynos and clinical cases are more frequently
attributed to multiple agents that act sequentially or synergistically to cause disease 234. In human
influenza, bacterial coinfection was identified as a critical factor in the mortality of the 1918
FLUAV pandemic 235,236. Lung specimens collected from 58 deceased influenza patients from
1918 to 1919 were positive for at least one bacterium in > 90% of cases 236. Most mixed
infection research has focused on viral-bacterial relationships and less is known regarding the
role of viral-viral coinfections in respiratory disease.
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Virus-Virus interactions
Viral coinfection is when two or more viruses infect the same host, although sometimes it
is defined more specifically as two or more closely related viruses infecting the same cell.
Coinfection implies concurrent infection but must be distinguished between single, sequential or
multiple exposures. Superinfection, bacterial or viral, is defined as a secondary infection
occurring after, or on top of, a primary infection. It implies an alteration in the host environment
favorable to the secondary pathogen. Virus-Virus interactions (VVIs) may be defined as a
difference in the course of infection of one virus as a result of a concurrent or prior infection by a
different species or strain of virus 237. Others have defined an interaction as “any process by
which infection caused by one pathogen affects the probability, timing, or natural history of
infection by another” 232.
VVIs, via incredibly diverse mechanisms, are broadly classified by three outcomes:
interference, enhancement, or accommodation 237,238. The most frequently observed VVI is
interference, or when replication of one virus prevents or inhibits multiplication of the other
virus. Viral interference has also been defined as a state of temporary immunity from infection
induced by viral infection 239 and the most common mechanism of viral interference is interferon
mediated. One virus triggers the host interferon response that nonspecifically blocks replication
of the other virus. Time of exposure and viral replication are critical factors. Viruses may also
compete for receptor binding or replication sites, metabolites, or other host support and this
competition can occur between closely related or unrelated viruses. In 2010, DePalma et al.
developed the first comprehensive, systematic framework for classifying 15 mechanisms of
VVIs into three main categories including direct interactions between the viruses, indirect
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interactions that result from alterations in the host environment, and immunological interactions
237

.
VVIs between influenza and other respiratory viruses are mostly competitive or neutral

including VVIs with respiratory syncytial virus, rhinovirus, human parainfluenza virus and other
influenza viruses 232. VVIs between Newcastle Disease virus (NDV)-LPAI and NDV-HPAI are
generally antagonistic, but VVIs between human immunodeficiency virus (HIV)-influenza
enhanced influenza infection 238. A mouse model of coinfection with unrelated respiratory
viruses, mildly pathogenic rhinovirus RV1B and virulent mouse-adapted PR8 influenza,
suggested there was interference 240. When the mild pathogen was administered 48 hours prior,
there was reduced disease severity at low and medium, but not high doses, of influenza. PR8
replication was not reduced but clearance was enhanced. Substituting RV1B for mouse hepatitis
virus strain 1 (MHV-1), suggested the exclusion was not virus specific, although MHV-1
infection was associated with reduced PR8 replication and upregulation of beta interferon. VVIs
have not been as extensively documented for influenza as other viruses. This may be partly
because influenza causes an acute and quickly cleared infection whereas VVIs are more likely to
occur in persistent viral infections (latent, chronic or slow infections) such as HIV and hepatitis
viruses and are an important consideration in pathogenicity 237. Influenza coinfection research
has frequently focused on reassortment between strains in a shared genus. This is not surprising
considering that all pandemics originated from reassortment; however, additional research is
needed to understand influenza VVIs beyond the context of reassortment and pandemic
preparedness.
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Epidemiological studies of respiratory coinfection
In human medicine, numerous studies have attempted to estimate the incidence of
coinfection in patients diagnosed with acute respiratory illness (ARI). Questions arise regarding
diagnostic limitations of detecting coinfections, differences in age of population most at risk,
whether coinfection correlates to increased disease severity or worse clinical outcome and
whether clinical outcomes differ for acute vs chronic disease. Advances in diagnostics,
including respiratory virus multiplex reverse transcriptase PCR, continued to improve detection
of mixed infections. Approximately 40% of patients with influenza-like illness (ILI) have virus
coinfections with FLUAV, FLUBV, respiratory syncytial virus, human rhinovirus, adenovirus,
human enterovirus, human metapneumonovirus, coronavirus, parainfluenza virus, human
bocavirus or others 241,242.
Many clinicians initially diagnose ILI with a FLUAV/FLUBV rapid test but FLUAVFLUBV coinfection is so uncommon that an additional PCR test must rule-out a false-positive
result 243. Few studies have identified coinfection rates between influenza viruses but one large
study of ILI patients that were PCR tested for 8 respiratory viruses had an overall coinfection
rate of 41% (10,501/25,596) with 7.3% (57/779) coinfected with seasonal FLUAV and another
respiratory virus and 2% (16/779) coinfected with seasonal FLUAV and FLUBV 242. Seasonal
FLUAV and FLUBV coinfection was associated with an increased risk of admission to ICU and
death 242. In the same study, 4.7% (137/2689) of patients were coinfected with pH1N1 FLUAV
and another virus, but none were coinfected with another influenza. Determining the clinical
significance of mixed infections has been far more challenging than detection. A 2014 metaanalysis of 21 studies (n = 4,280 patients), identified no differences in clinical disease severity
between viral coinfections and single respiratory infections 244. A 2016 meta-analysis of 43
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studies (n = 17, 234 patients under the age of 18) found no statistically significant difference in
clinical outcomes between the single and multiple infections 245. Outcomes assessed included
need for hospitalization, length of hospital stay, use of supplemental oxygen, mechanical
ventilation, admission to the intensive care unit and death.
Laboratory studies of influenza co-infection
Superinfection exclusion (SIE) is a specific type interference that occurs when a
preexisting viral infection prevents a secondary infection with the same or a closely related virus
246

. This phenomenon was discovered in 1929 when plants infected with tobacco mosaic virus

(TMV) were later resistant to infection with TMV variants 247,248. Viral interference research
continued in plant viruses, extended to animal viruses and was soon identified in influenza
viruses 248. In 1944, Ziegler and Horsfall demonstrated SIE between A/PR 8/34 (H1N1), Shope’s
1976 swine influenza 249 and the Lee strain of FLUBV 250 and also identified key temporal and
dose-dependent outcomes. Chick embryos inoculated with secondary challenge at 24 hours at
equally small doses (10 EID) demonstrated complete reciprocal interference (i.e. irrespective of
the order of primary and secondary virus). However, there was no interference with
simultaneous, equal dose inoculation. There was partial interference at four and eight hours and
complete interference by 12 hours. When an unequal dose was used for primary and secondary
inoculation, there were strain specific variations in interference. A small dose of PR8 caused
interference even in the presence of a large secondary dose of Lee. However, a small dose of Lee
could not cause interference of a large secondary dose of PR8, demonstrating influenza VVI
outcomes are strain, dose and time dependent.
Contemporary studies also demonstrate influenza SIE although the mechanisms that
regulate it are poorly understood. A study of A549 human epithelial cells infected with H1N1
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and H3N2 suggested that the NA protein limits superinfection for 6 hours post-primary infection
251

. A different study showed that a six hour delay produced robust SIE, whereas simultaneous

inoculation resulted in coinfected cells approaching 100% 252. Similar results were obtained
using Vero cells that lack type I interferon secretion, suggesting SIE does not depend on IFN
secretion 252 . Their data also suggested that although NA enzymatic activity correlated with
higher SIE, it wasn’t dependent upon NA activity but rather by the number of viral genes and
MOI 252.
The temporal aspects of SIE must also be considered. An in vitro MDCK assay and an in
vivo guinea pig model compared reassortment efficiency in synchronous and sequential
coinfections in the absence of segment mismatch using seasonal H3N2 variants, rPAN/99wt and
rPan/99var 253. High MOI synchronous infection led to an 88.4% reassortant rate but this
decreased to 47.5% at an eight hour infection interval and only 4.75% at a 12 hour interval 253. In
the guinea pig model, there was moderate reassortment at 0 and 6 hour intervals, robust
reassortment at 12 hours, minimal reassortment at 18 hours and no reassortment at 24, 48 or 72
hour intervals 253. Another recent study used a viral RNA labeling design to quantify coinfection
of FLUAV WSN/33 (H1N1) in MDCK cells and showed the secondary virus had to coinfect
cells within two to three hours of the primary virus to be successful and after this timepoint the
secondary virus was restricted for the duration of the infection 254. The secondary virus was still
capable of entering the cell but could not shift to replication, suggesting replication of the
primary virus impaired nuclear import of the gene segments 254. A ferret animal model compared
coinfection of antigenically unrelated FLUAV vs FLUBV and heterosubtypic FLUAV (H1 and
H3) with the secondary challenge occurring 1,3,5,7, 10, and 14 days post primary challenge 239.
Viral interference depended upon the time interval between infections and the sequential
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combination of viruses. When FLUAV pH1N1 was administered one or three days prior to
FLUBV, half of the ferrets did not shed FLUBV but if FLUBV was the primary challenge, the
ferrets became coinfected and shed both viruses.
Knowledge Gaps and Objectives of this Dissertation
Emerging pathogens pose a substantial and persistent risk to human and animal health.
The research objectives of this dissertation are to characterize the prevalence, pathogenicity and
zoonotic risk of emerging influenza viruses from domestic species with special attention to dogs
and pigs. We seek to characterize the pathogenicity of reassortant FLUAV viruses and the
relationship between coinfection with unrelated influenza species, FLUAV and emerging
FLUDV. Chapter two characterizes the zoonotic risk, pathogenesis and transmission of avianorigin CIV-H3N2 and reassortant progeny with 2009 pH1N1. The rationale for this study is that
dogs are susceptible to avian and mammalian FLUAV and may serve as a mixing vessel for
strains with pandemic potential. Furthermore, CIV-H3N2 x pH1N1 wild-type reassortants have
been isolated from dogs, suggesting a compatibility between gene segments. We generated
reassortant progeny from coinfection of CIV-H3N2 and 2009 pH1N1 and evaluated these
reassortants for their pathogenicity in mice and ferrets and transmissibility in ferrets. We
characterized the 127 theoretically possible reassortant viruses as high growth, moderate growth,
or unable to generate allowed us to identify specific reassortants that might pose the most risk.
We selected 19 reassortant viruses for study in mice and one reassortant for pathogenicity and
transmission in ferrets. The reassortant efficiently transmitted by contact, but not airborne route,
and was pathogenic in ferrets. Our results suggest that CIV-H3N2 reassortants may pose a
moderate risk to public health and that the canine host should be monitored for emerging
FLUAVs.
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In chapter 3, we utilized a sera bank of shelter-owned dogs in Mississippi to perform a
seroepidemiological analysis of FLUAV exposure in shelter-owned dogs in Mississippi. Our
hypothesis was that the seroprevalence would be low (~ 2-3%); however, there is no available
information regarding FLUAV exposure in Mississippi dogs. Dogs housed in shelters, boarding
facilities, etc. are at increased risk for CIV; however, this increased risk seems to be limited to
urban shelters with large populations of dogs and higher rates of inter-facility transfer. Our
results identified only 0.35% (2/565) dogs as ELISA positive and one of these positive dogs was
tested only one day after intake into the shelter, suggestive of non-shelter FLUAV exposure. Our
results suggest shelter-owned dogs in Mississippi have minimal exposure to FLUAV.
Finally, in chapter four, we investigate a recently emerged FLUDV by characterizing the
pathogenicity of FLUDV and FLUAV coinfection in domestic pigs. Serological evidence
suggests that FLUAV and FLUDV coinfection may play a role in the ecology and epidemiology
of influenza in feral swine. Transmission of emerging diseases from wildlife, including influenza
from feral swine to domestic swine, poses a biosecurity risk 255. Other studies have established
FLUDV as a pathogen in domestic and feral swine, although tissue tropism has differed
somewhat across studies. Therefore, our objectives were to compare the pathogenicity and tissue
tropism of FLUAV, FLUDV and FLUDV + FLUAV coinfection in domestic swine. Although
viral and bacterial pathogens are frequently synergistic, less is known regarding virus-virus
coinfections. FLUDV has never been studies in a virus-virus coinfection model. Collectively,
these research objectives will increase our knowledge of the risks of emerging influenza viruses,
including CIV and FLUDV, from domestic veterinary species.
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CHAPTER II
ZOONOTIC RISK, PATHOGENESIS, AND TRANSMISSION OF AVIAN-ORIGIN H3N2
CANINE INFLUENZA VIRUS
The work of this chapter was published in 2017 in the Journal of Virology 256.
Copyright © 2017, American Society for Microbiology, [Journal of Virology Oct 2017, 91 (21)
e00637-17; DOI: 10.1128/JVI.00637-17]
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Risk, Pathogenesis, and Transmission of Avian-Origin H3N2 Canine Influenza Virus." J Virol
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Abstract
Two subtypes of influenza A virus (FLUAV), avian-origin canine influenza virus H3N2 (CIVH3N2) and equine-origin CIV-H3N8, are enzootic in the canine population.

Dogs have

demonstrated seroconversion to diverse FLUAVs and naturally occurring reassortants of CIVH3N2 and the 2009 H1N1 pandemic virus (pdmH1N1) have been isolated. We conducted a
thorough phenotypic evaluation of CIV-H3N2 in order to assess its threat to human health. Using
ferret-generated antisera we determined that CIV-H3N2 is antigenically distinct from
contemporary human H3N2 FLUAV, suggesting there may be minimal herd immunity in humans.
We assessed the public health risk of CIV-H3N2pdmH1N1 reassortants by characterizing in vitro
genetic compatibility and in vivo pathogenicity and transmissibility. Using a luciferase
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minigenome assay, we quantified the polymerase activity of all possible 16 ribonucleoprotein
(RNP) complexes (PB2, PB1, PA, NP) between CIV-H3N2 and pdmH1N1 identifying some
combinations that were more active than either parental virus complex. Using reverse genetics,
and fixing the CIV-H3N2 HA, we found that 51 of the 127 possible reassortant viruses were viable
and able to be rescued. Nineteen of these reassortant viruses had high in vitro growth phenotypes
and 13 of these replicated in mice lungs. A single reassortant with the NP and HA gene segments
from CIV-H3N2 was selected for characterization in ferrets. The reassortant efficiently transmitted
by contact but not airborne routes and was pathogenic in ferrets. Our results suggest that CIVH3N2 reassortants may pose a moderate risk to public health and that the canine host should be
monitored for emerging FLUAV.
Importance
FLUAV pandemics are caused by the introduction of novel viruses that are capable of
efficient and sustained human transmission into a human population with limited herd immunity.
The dog, as a potential “mixing vessel” for avian and mammalian FLUAVs, is a unique host due
to their susceptibility to infection, large global population and close physical contact with
humans. Our results suggest that humans are likely to have limited preexisting immunity to CIVH3N2 and that CIV-H3N2pdmH1N1 reassortants have moderate genetic compatibility and are
transmissible by direct contact in ferrets. Our study contributes to the increasing evidence that
FLUAV surveillance in the canine population is an important component of pandemic
preparedness.
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Introduction
FLUAV, a member of the family Orthomyxoviridae, is an enveloped virus with eight
single-stranded, negative-sense RNA genomic segments 257,258. Migratory waterfowl are the
natural reservoirs of FLUAV although diverse species are susceptible, including domestic
poultry, pigs, dogs, horses, and sea mammals and humans 63,259-262. FLUAV subtypes are
determined by two viral surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) and
18 HA and 11 NA subtypes have been identified 27. FLUAV diversity is maintained through the
mechanisms of genetic drift and genetic shift. Genetic drift results from the accumulation of
mutations whereas genetic shift occurs when two different FLUAVs intermix via a co-infected
host cell and one or more genomic segments are exchanged. Antigenic shift occurs when the
reassortant virus has altered antigenicity. Both mechanisms of diversity can alter the virulence
and pathogenicity in the host and/or alter host range. A zoonotic reassortant virus may generate a
pandemic when there is little or no pre-existing human immunity and the virus is capable of
transmitting efficiently among humans, as occurred in 1957 and 1968 263 and in 2009 264.
Dogs warrant special consideration as an influenza host due to several factors. Their
large global population is difficult to quantify but a recent estimate is ~700 million 199, many
with close human contact. Dogs are susceptible to avian and mammalian FLUAVs and may act
as “mixing vessels” for promoting reassortment 194,195. Two major CIV subtypes, H3N8 and
H3N2, are currently circulating in the global canine population. Equine-origin H3N8 (CIVH3N8) was identified in 2004 at a Greyhound racing track in Florida, United States (U.S.) 137
and was subsequently detected in Canada 265, the United Kingdom 175, and Australia 266. CIVH3N8 is now enzootic among the U.S. canine population with the virus being reported in dogs in
more than 40 states 267. Avian-origin H3N2 (CIV-H3N2) was first identified in South Korea in
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2007 and later detected in China and Thailand 183-185 and other areas of Southeast Asia 186-189.
CIV-H3N2 was first isolated from dogs outside of Asia in the April 2015 outbreak in the
Midwestern U.S. which affected more than 1,000 dogs 190.
As early as the 1970s serological evidence in the U.S. suggested dogs could become
infected with human strains of H3N2 136,205. More recent serological evidence suggests that dogs
have been naturally infected with human seasonal H1N1 and H3N2 180, avian H5N1 201, H5N2
202

, H9N2 203, H10N8 204 and pdmH1N1 206. In China, more than 20% of domestic dogs were

shown to have serum antibodies for pdmH1N1 and dogs with positive antibody titers for both
CIV-H3N2 and pdmH1N1 have been identified 187,208. During a surveillance effort in 2012,
researchers identified a virus isolate that contained the hemagglutinin gene segment from CIVH3N2 and the remaining 7 gene segments from pdmH1N1 209; more recently, another isolate was
identified that contained the matrix gene segment from pdmH1N1 and all other gene segments
from CIV-H3N2 210.
The unique relationship of dogs and humans, the serological evidence of dogs infected
with diverse FLUAVs including two enzootic CIV subtypes, and the isolation of naturally
occurring reassortant viruses in dogs are all factors that raise concerns that a novel virus with
potential risk to public health may emerge in the canine population. Because of these concerns,
we conducted a study to 1) characterize the genetic compatibility of pdmH1N1 and CIV-H3N2
viruses, 2) detect the growth phenotype of pdmH1N1CIV-H3N2 reassortant viruses in vitro,
and 3) assess the pathogenicity and transmissibility of these reassortant viruses in mice and
ferrets.
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Materials and Methods
Cells
Madin-Darby canine kidney (MDCK) cells (ATCC® CCL-34) and human embryonic
kidney epithelial (293T) cells (ATCC® CRL-11268) were maintained in Dulbecco’s Modified
Eagle Medium (Gibco/BRL) supplemented with 10% fetal bovine serum (Atlanta Biologicals)
and penicillin–streptomycin (100 U/ml and 100 µg/ml, respectively) (GIBCO/BRL) at 37°C with
5% CO2. Human lung adenocarcinoma epithelial (A549) cells (ATCC® CCL-185) were
maintained in F-12K (Kaighn’s Modification of Ham’s F-12 Medium; ATCC®) supplemented
with 10% fetal bovine serum and penicillin–streptomycin (100 U/ml and 100 µg/ml,
respectively) at 37°C with 5% CO2.
Viruses
We propagated CIV strain A/canine/Guangdong/1/2006(H3N2) herein referred to as GD06, the
first H3N2 isolate identified from dogs in southern China 183, in 9- to 11-day-old specific
pathogen free (SPF) embryonated chicken eggs (Sunrise Farms) and MDCK cells. The pandemic
H1N1 strain used for experiments was A/California/4/2009(H1N1) herein referred to as CA09.
We also used A/PR/8/1934(H1N1), abbreviated as PR8.
Mice and Ferrets
All animal experiments were performed in MSU AAALAC accredited facilities and in
compliance with MSU IACUC and IBC protocols. We obtained 4-month-old female SPF ferrets
from Triple F Farms and 6- to 8-week-old female SPF BALB/c mice from Harlan Laboratories.
All animals were maintained in individually ventilated caging in compatible groups (mice) or in
pairs that were individually separated by a partition (ferrets). All ferrets were tested and
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determined to be free from influenza viral antibodies before initiating the study. Water and food
were available ad libitum. We generated ferret antisera against temporally representative human
H3N2 FLUAVs from 1979 to 2015 as previously described (37) for use in evaluating the
antigenic similarity between CIV-H3N2 and contemporary human H3N2 FLUAVs. Ferret
antisera was raised against A/Bangkok/1/1979 (H3N2), A/Philippines/2/82 (H3N2),
A/Caen/1/1984 (H3N2), A/Mississippi/1/1985 (H3N2), A/Leningrad/360/1986 (H3N2),
A/Sichuan/02/1987 (H3N2), A/Sichuan/60/1989 (H3N2), A/Ann Arbor/03/1993 (H3N2),
A/Johannesburg/33/1994 (H3N2), A/Nanchang/933/1995 (H3N2), A/Sydney/5/1997(H3N2), and
A/Wisconsin/67/2005 (H3N2), A/Brisbane/10/2007 (H3N2), A/Perth/16/2009 (H3N2),
A/Victoria/361/2011 (H3N2), A/Texas/50/2012 (H3N2), A/Switzerland/9715293/2013 (H3N2),
A/Utah/07/2013 (H3N2), A/Mississippi/17/2013 (H3N2), A/Costa Rica/4700/2013 (H3N2),
A/Palau/6759/2014 (H3N2), A/Hong Kong/4801/2014 (H3N2), A/Fiji/2/2015 (H3N2),
A/Brisbane/82/2015 (H3N2) and A/Victoria/503/2015 (H3N2). We also generated ferret antisera
against CIV-H3N8, specifically A/canine/Iowa/13628/2005 (H3N8).
RNA Isolation, PCR, Cloning, and Plasmid Extraction
GD06 viral RNA was isolated using an RNeasy Mini Kit (Qiagen) and amplified using
SuperScript One-Step RT-PCR with Platinum Taq (Invitrogen), and amplicons were cloned into
a dual-promoter plasmid vector, pHW2000, as previously described 268,269. All plasmids were
amplified using the GeneJET Plasmid Midi Prep Kit (Thermo Fisher Scientific) according to the
manufacturer’s protocol and confirmed via Sanger sequencing at the Life Sciences Core
Laboratories Center (Cornell University, Ithaca, New York, USA).
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Generation of Reassortant Viruses Using Reverse Genetics
We used reverse genetics to generate reassortant viruses with all possible genomic
constellations between GD06 and CA09 with the HA gene originating only from the wild-type
GD06 (i.e., 27 or 127 reassortants all with the HA gene from GD06). We generated the
reassortant viruses using transfection and reverse genetics as previously described 270. In brief, 1
μg of each of the eight plasmids for the specified genomic constellation was added to Opti-MEM
(Gibco/BRL) and 16 µL of TransIT-LT1 Transfection Reagent (Mirus Bio) and mixed gently;
the mixture was incubated at room temperature for 45 min. Opti-MEM (800 µL) was then added
to the mixture, which was then transferred to cocultured MDCK and 293T cells. The transfection
medium was removed from the cells 12 h after transfection and replaced with Opti-MEM
supplemented with TPCK treated Trypsin from bovine pancreas (TPCK-Trypsin) (SigmaAldrich). Three days after transfection, the supernatant was seeded once into MDCK cells.
Approximately 72 hours later 50 µL of P1 was used in a hemagglutination assay with 0.5%
turkey erythrocytes. Of the 127 reassortants, 51 showed hemagglutination and were collected and
stored at −80°C for additional characterization. All others that we failed to generate were
repeated from the beginning, i.e. transfection. However, no additional reassortants were
generated. Titers for the 51 reassortant viruses were determined by using endpoint titration in
MDCK cells, and TCID50 was calculated by using the Reed-Muench method 271. The limit of
virus detection was 100.699 TCID50/ml. All viruses with a predetermined cut-off of >106
TCID50/ml were selected for further pathogenesis characterization in mice. Illumina sequencing
confirmed the full gene segments of each virus, and genomic sequencing and assembly are
described elsewhere 272.
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Growth Curve Replication Kinetics in Vitro
To determine virus replication kinetics in vitro, we quantified and infected MDCK and
A549 cells at a multiplicity of infection (MOI) of 0.001 TCID50/ml. After incubation at 37°C for
1 h, cells were washed twice with phosphate-buffered saline (PBS) and incubated in Opti-MEM,
containing TPCK-Trypsin, at 1 µg/ml (MDCK cells) or 0.5 µg/ml (A549 cells) at 37°C with 5%
CO2. Supernatants were collected at 12, 24, 36, 48, and 72 h post-inoculation and stored at
−80°C. Supernatants were titrated in MDCK cells by TCID50 and calculated by using the ReedMuench method 271. Titers are shown as the means of the three replicate infections. The limit of
virus detection was 100.699 TCID50/ml.
Hemagglutination and hemagglutination inhibition (HI) Assays
To detect the virus titer and to determine seroconversion, we performed the hemagglutination
assay and HI assay using 0.5% turkey erythrocytes as described elsewhere 273. All HI assays
were performed in three replicates.
Luciferase Assay to Quantify RNP
A total of 4 ×104 293T cells were transfected with polymerase protein expression
plasmids PB2, PB1, PA, and NP (40 ng) in Corning® 96 well plates. 40 ng of plasmid phPOLIRLUC expressing Renilla luciferase and 4 ng of pGL4.13 [luc2/SV40] expressing firefly
luciferase (internal control) (Promega, Madison, WI) were also cotransfected in 293T cells.
Luciferase activities were measured in lysates from cells harvested at 48 h after transfection
using Dual-Luciferase Reporter Assay System (Promega, Madison, WI) per manufacturer’s
instructions. We measured the Renilla/firefly luciferase activities for the sixteen possible
combinations of RNP plasmids derived from CA09 and GD06, determining the replication
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efficiency of each combination. The ratio of Renilla/firefly luciferase activities for each RNP
combination was normalized to the Renilla/firefly luciferase activity of the internal control.
Luciferase data were expressed as means ± standard deviations of three independent
experiments. The differences in means were tested using a one-way ANOVA with post-hoc
Tukey’s multiple-comparison test using Graphpad Prism version 7.02 (GraphPad Software, Inc.,
La Jolla, CA). The values p< 0.05 were considered statistically significant.
Pathogenesis in Mice
We characterized the pathogenesis of the reassortant viruses by inoculating with 22
viruses, including: 19 high growth reassortants between GD06 and CA09 (Table 2); one
reassortant GD06× PR8 with the HA and NA gene segments derived from GD06; and the wildtype GD06 and CA09. Briefly, we anesthetized 22 groups of mice (n=8 mice per group) with
isoflurane and then intranasally inoculated them with 50-µL of an FLUAV at 106 TCID50 per ml
or with 50 µL of sterile PBS. All mice were weighed daily, and at 4 days post-inoculation (dpi),
we humanely euthanized three mice in each group and collected lung tissues under sterile
conditions. Lung tissues were stored at −80°C until virus titers could be obtained. We used a
pestle (Research Products International) and silicon dioxide (Acros Organics/Thermo Fisher
Scientific) to homogenize lung tissues in 500 µL of sterile PBS and then titrated the supernatants
in MDCK cells. TCID50 was determined by using the Reed-Muench method 271. The limit of
virus detection was 100.699 TCID50/ml. Mean viral lung titers were tested using a one-way
ANOVA with post-hoc Tukey’s multiple-comparison test using Graphpad Prism version 7.02
(GraphPad Software, Inc., La Jolla, CA). The values p< 0.05 were considered statistically
significant. The reassortant virus with the highest lung titer (i.e. reassortant 109) was selected for
a transmission and pathogenesis study in ferrets. The remaining five mice in each group were
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monitored for weight loss until 14 dpi and then humanely euthanized. Serum was collected to
determine seroconversion.
Transmission and Pathogenesis in Ferrets
To determine the transmissibility and pathogenesis of GD06 and reassortant 109 in
ferrets, 4-month-old female ferrets were purchased from Triple F Farms and given 7 days to
acclimatize after arrival. Each ferret was weighed and its temperature monitored throughout the
experiment using implanted transponders (Bio Medic Data Systems, Inc.). Before the
experiments were conducted, all 24 ferrets tested seronegative for antibodies against GD06,
CA09, A/Perth/16/2009 (H3N2), A/Victoria/361/2011(H3N2), and
A/Minnesota/307875/2012(H3N2) influenza viruses. Each experiment group included three
ferrets that were lightly anesthetized with isoflurane and inoculated intranasally with either
GD06 or reassortant 109 (106 TCID50 viral load in a 1-ml volume) and three ferrets for exposure
susceptibility that were not anesthetized or inoculated. The exposure ferrets were exposed to the
virus through either ferret-to-ferret direct contact or indirect (i.e., aerosol) contact with the virusinoculated ferret.
In each of the three direct contact transmission groups, one virus-inoculated ferret and
one exposure ferret were pair housed in the same cage without a partition. In each of three
aerosol transmission groups, one virus-inoculated ferret and one exposure ferret were pair
housed in the same cage but were separated individually by a 1 cm–thick, double-layered, steel
partition with 5-mm perforations (Allentown, Inc.). In all cages, the exposure ferret was placed
into the cage one day after the virus-inoculated ferret was introduced to the cage. The nonrecirculating airflow in the cage went from the exposure ferret through the partition to the virusinoculated ferret and exhausted to room air through HEPA filtration.
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Ferrets were lightly anesthetized and induced to sneeze in order to collect nasal wash
fluids at 3,5,7 and 10 dpi to determine viral shedding patterns. Briefly, ferrets were induced to
sneeze by inoculating 1 mL of sterile PBS and gently tickling the nasal cavity with a sterile
cotton swab. Before performing nasal washes, we measured each ferret’s body temperature and
weight. We monitored clinical signs daily. Virus titers in the samples were determined by
titration in MDCK cells. To evaluate replication efficiency and pathology of the viruses in the
ferret respiratory tract, we euthanized two of the three virus-inoculated ferrets in each direct
contact transmission group at 5 dpi. Turbinate, trachea, bronchi, and lungs were collected and
virus titers were determined. For the remainder of the ferrets, serum was collected at 14 dpi,
immediately before they were euthanized.
Ethics Statement
Animal experiments involving mice and ferrets were conducted in compliance with the
Institutional Biosafety Committee and the Institutional Animal Care and Use Committee of
Mississippi State University approved protocols (IBC#011-12 and IACUC#13-022) and under
the regulations of the Animal Welfare Act (AWA). Viruses were propagated in 9- to 11-day-old
SPF embryonated chicken eggs (Sunrise Farms). Laboratory experiments were conducted under
BSL-2 conditions with investigators wearing appropriate personal protective equipment. All
reassortants viruses were generated before the U.S. Government pause on gain-of-function
research.
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Results
GD06 is Antigenically Distinct from Seasonal H3N2 viruses
We performed HI assays to detect the cross-reactivity between GD06 and ferret antisera
raised against a representative set of human seasonal H3N2 viruses as previously reported 274 and
we also tested additional contemporary viruses. Test sera included ferret generated antisera
against 25 H3N2 viruses from 1979-2015 (Table 2.1). Results showed weak cross-reactions of
1:20 between GD06 virus A/Nanchang/933/1995 antiserum and 1:40 between GD06 virus and
A/Sydney/5/1997 antiserum. However, there was a titer of <1:20 between GD06 and all other
with ferret antisera raised against the remaining human H3N2 seasonal influenza viruses. The
homologous titers for GD06 virus against GD06 ferret antiserum was 1:1,280. In addition, the HI
titer between GD06 and ferret antiserum raised against A/canine/Iowa/2005 (H3N8) was 1:40.
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Table 2.1

HI data of ferret antisera tested against GD06 and representative human FLUAV
Ferret antisera

A/Bangkok/1/1979 (H3N2)
A/Philippines/2/82 (H3N2)
A/Caen/1/1984 (H3N2)
A/Mississippi/1/1985 (H3N2)
A/Leningrad/360/1986 (H3N2)
A/Sichuan/02/1987 (H3N2)
A/Sichuan/60/1989 (H3N2)
A/Ann Arbor/03/1993 (H3N2)
A/Johannesburg/33/1994 (H3N2)
A/Nanchang/933/1995 (H3N2)
A/Sydney/5/1997(H3N2)
A/Wisconsin/67/2005 (H3N2)
A/Brisbane/10/2007 (H3N2)
A/Perth/16/2009 (H3N2)
A/Victoria/361/2011 (H3N2)
A/Texas/50/2012 (H3N2)
A/Switzerland/9715293/2013 (H3N2)
A/Costa Rica/4700/2013(H3N2)
A/Utah/7/2013(H3N2)
A/Mississippi/17/2013(H3N2)
A/Hong Kong/4801/2014 (H3N2)
A/Palau/6759/2014 (H3N2)
A/Fiji/2/2015(H3N2)
A/Brisbane/82/2015(H3N2)
A/Victoria/503/2015(H3N2)
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HI Titer

Homologous Titer

<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
1:20
1:40
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20
<1:20

1:2560
1:1280
1:1280
1:2560
1:320
1:320
1:480
1:120
1:480
1:720
1:960
1:1280
1:1280
1:640
1:640
1:1280
1:640
1:1280
1:640
1:320
1:1280
1:1280
1:640
1:1280
1:640

GD06 and CA09 Gene Segments Showed High Compatibility
To characterize genomic compatibility between GD06 and CA09, we successfully
generated 51 of 127 reassortants (40%). We determined the growth phenotype of these 51
reassortants and classified them as high growth (> 106 TCID50/ml in MDCK cells) (n=19) (Table
2.2) or moderate growth (<106 TCID50/ml in MDCK cells) (n=32) (Table 2.3). A total of 76 of
127 reassortants (60%) could not be generated from a single transfection and propagation
attempt (Table 2.4). Although the genomic constellations of the 51 reassortants showed that all 7
gene segments of each virus were represented, the gene segments were unequally represented.
Among the 51 reassortants generated, GD06 gene segments were underrepresented whereas
CA09 gene segments were overrepresented. The NA, PB1 and PB2 gene segments from GD06
were present in only 11 reassortants (22%), 14 (27%) and 17 of 51 reassortants (33%),
respectively. The other gene segments were more equally distributed among the 51 reassortants.
The NP, M, NS and PA gene segments from GD06 were present in 24 (47%), 25 (49%), 25
(49%) and 31 of 51 (61%) reassortants, respectively. However, among the high-growth (>106
TCID50/mL) reassortant viruses, all 19 contained the PB1 gene segment from CA09 and 16/19
(~84 %) contained the PB2 gene segment from CA09.

45

Table 2.2

Reassortant Viruses Expressing a High Growth Phenotypea
Genome Constellations

Virus
name
7
10
22
23
27
31
55
63
71
75
83
87
95
99
107
109
111
115
126

PB2

PB1

PA

HA

NP

NA

M

NS

Viral titer
(log10 TCID50)
7.2
7.2
6.4
7.9
6.9
7.5
7.2
7.5
6.2
6.2
6.5
7.2
7.5
6.4
6.4
6.2
6.2
7.7
6.3

high-growth phenotype was growth of >106 TCID50/ml. Data are for 19 reassortants.
Reassortant viruses were generated from transfection of cocultured MDCK and 293T cells with
plasmids from CA04 viruses (shaded in purple) and GD06 viruses (shaded in brown), and virus
titers were obtained after a single propagation in MDCK cells.
aA
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Table 2.3

Reassortant viruses expressing a moderate-growth phenotypea
Genome Constellations

Virus
Viral titer
PB2 PB1 PA
HA
NP
NA
M
NS
name
(log10 TCID50)
11
5.4
15
5.4
17
5.4
19
5.3
25
5.2
30
5.7
35
5.7
41
4.7
43
5.7
49
5.7
51
5.2
54
5.0
56
2.7
57
5.4
58
4.9
59
5.2
62
5.5
80
4.7
81
4.5
82
3.9
86
5.7
88
4.8
89
3.5
91
4.9
94
5.7
112
4.9
113
5.7
114
4.4
118
5.2
120
4.4
121
5.7
123
5.5
a A moderate-growth phenotype was growth of < 106 TCID /ml. Data are for 32 reassortants.
50
Reassortant viruses were generated from transfection of cocultured MDCK and 293T cells with
plasmids from CA04 viruses (shaded in purple) and GD06 viruses (shaded in brown), and virus
titers were obtained after a single propagation in MDCK cells.
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Table 2.4

Genomic constellation of reassortant viruses that could not be generated
Genome Constellations

Virus
name
1
2
3
4
5
6
8
9
12
13
14
16
18
20
21
24
26
28
29
32
33
34
36
37
38
39
40
42
44
45
46
47
48
50
52
53
60
61
64

PB2

PB1

PA

HA

NP

48

NA

M

NS

Viral titer
(log10 TCID50)
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699
<0.699

Table 2.4 (continued)
65
<0.699
66
<0.699
67
<0.699
68
<0.699
69
<0.699
70
<0.699
72
<0.699
73
<0.699
74
<0.699
76
<0.699
77
<0.699
78
<0.699
79
<0.699
84
<0.699
85
<0.699
90
<0.699
92
<0.699
93
<0.699
96
<0.699
97
<0.699
98
<0.699
100
<0.699
101
<0.699
102
<0.699
103
<0.699
104
<0.699
105
<0.699
106
<0.699
108
<0.699
110
<0.699
116
<0.699
117
<0.699
119
<0.699
122
<0.699
124
<0.699
125
<0.699
127
<0.699
Gene segments are shaded CA04 (purple) and GD06 (brown). Data are for 72 genomic
constellations that could not be generated (i.e. titers below the limit of virus detection of 100.699
TCID50/ml) from transfection of cocultured MDCK and 293T followed by a single propagation in

MDCK cells.
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Reassortant RNP complexes showed enhanced luciferase activity
The ribonucleoprotein (RNP) complex consists of PB2, PB1, PA, and NP proteins and
viral RNA and is responsible for the replication and transcription activity of FLUAV. Evidence
suggests that RNP complex compatibility functions as a restricting factor and critical component
of FLUAV reassortment 275. There is also evidence of a correlation between enhanced
polymerase activity and pathogenicity of FLUAV 276,277. We used a minigenome luciferase assay
to quantify the polymerase activity of the 16 RNP complex constellations possible from GD06
and CA09. The CA09 RNP complex and GD06 complex did not show a statistically significant
difference (p value > 0.05) in luciferase activity (Figure 2.1). We compared the luciferase
activity of the 14 reassortant RNP complexes to those of the two wild-type RNP complexes and
found that four reassortants expressed significantly greater luciferase activity. These four
reassortant RNP complexes shared two common traits: they all contained the NP gene segment
from GD06 and the PB1 gene segment from CA09. The RNP complex with the greatest
luciferase activity was GD06PB2CA09PB1CA09PAGD06NP which had approximately 11 times the
luciferase activity of CA09 and GD06 (p value <0.0001). The RNP complex with the next
highest luciferase activity was CA09PB2CA09PB1CA09PAGD06NP which had approximately six
times the activity of CA09 and GD06 (p value <0.0001). Reassortants
CA09PB2CA09PB1GD06PAGD06NP and GD06PB2CA09PB1GD06PAGD06NP had approximately
three times the activity of CA09 and GD06 (p value <0.001).
We compared the RNP luciferase activities with the frequency of reassortant viruses generated
in vitro to look for possible correlations. A total of 18 out of 51 (~35%) of the reassortant viruses
consisted of one of the four high luciferase activity RNP complexes (Figure 2.1). Three RNP
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complex constellations were never generated in any of the reassortant viruses and these also
correlated to the lower end of RNP luciferase activity.
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Figure 2.1

Ribonucleoprotein Complex Luciferase Activity and Reassortant Virus Frequency

The RNP luciferase activity was compared for all 16 RNP complexes between GD06 (shaded in
brown) and CA09 (shaded in purple). Rluc/Fluc ratio is expressed as the mean of three
independent experiments and statistical analysis was performed using a one-way ANOVA with
post-hoc Tukey multiple-comparison test. The reassortant virus RNP data was a frequency count
(n=51) from Table 2.2 (n=19) and Table 2.3 (n=32).
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Reassortant viruses caused minimal weight loss in mice
To characterize the pathogenicity of the reassortant viruses, 22 viruses were used to
intranasally inoculate mice (n=8): 19 high-growth (>106 TCID50/mL) reassortants (Table 2.2),
GD06, CA09, and a reassortant GD06xPR8. Pathogenicity was determined by measuring weight
loss and viral lung titers. Overall, weight loss was minimal or none among the infected mice.
We used weight loss >5% as a pre-defined marker of pathogenicity; however, there was
considerable variation among the individual mice, thus limiting the usefulness of the weight-loss
data. Weight loss was observed in mice infected with reassortant 111 at 13.6% + 5.5% at 3 dpi
(Figure 2.3). Mice infected with reassortant 109 showed a weight loss of 7.6% + 6.4% at 8 dpi
and mice infected with reassortant 55 showed a weight loss of 6.1% + 4.3 % at 7 dpi. Mice
infected with GD06 or reassortants 22, 27, 75, 83, 87, 99, 115, and 126 showed no weight loss.
The remaining reassortants and CA09 resulted in minimal weight loss in mice (i.e. <5%).
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Figure 2.2

Body weight variation in infected mice

Mice were intranasally inoculated with 106 TCID50 of virus and body weights were recorded
every day thereafter. Variation in body weights are expressed as mean ± standard deviation. The
greatest weight loss was observed at 3 dpi in mice infected with reassortant 111 at 13.6% +
5.5%.
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Reassortant viruses replicated to high titers in mice lungs
To detect viral replication in vivo, we humanely euthanized three mice per group at 4 dpi
and collected lung tissues for titration in MDCK cells. Mice infected with reassortant viruses 7,
10, 75, 83, 99, and 107 had viral lung titers at or below the level of detection (0.699
log10TCID50/mL), whereas all other reassortants had titers above the level of detection (Figure
2.3). Mice infected with CA09 showed significantly higher lung titers than GD06 at 6.2 (± 0.5)
log10TCID50/mL versus 3.0 (± 0.07) log10TCID50/mL, respectively (p value = < 0.0001; 1-way
ANOVA with post-hoc Tukey’s test). The reassortant that replicated to the maximum titer in
mice lungs was reassortant 109 at 5.8 (± 0.7) log10TCID50/mL. Reassortant 109 replicated to a
significantly higher titer in mice lungs for 15 of the 21 testing viruses, including reassortants 7,
10, 75, 83, 99, 107, 27, 71, 22 and 31 (p value = < 0.0001), GD06 (p value = 0.0008), CIV-PR8
(p value = 0.0077), reassortant 63 (p value = 0.0089) and reassortant 115 (p value 0.0029) and
GD06xPR8, (p value 0.0077) (1-way ANOVA with post-hoc Tukey’s test). There was no
significant difference in mice viral lung titer between reassortant 109 and the remaining six
testing viruses which includes reassortants 95, 23, 55, 87, 126 or pH1N1 (p value = > 0.05; 1way ANOVA with post-hoc Tukey’s test). Reassortant 109 had NP and HA gene segments from
GD06 and all other gene segments from CA09.
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Figure 2.3

Viral lung titers of inoculated mice

Mice (n=3) were intranasally inoculated with 50ul of 106 TCID50 per ml of virus. At 4 dpi they
were necropsied and lung tissues were collected for determining virus titers.
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Most infected mice seroconverted
We collected sera from the mice at 14 dpi to determine whether seroconversion had occurred.
Seroconversions were determined by HI assay, as previously described with titers >20 defined as
seroconversion 273. Of the 110 mice (i.e. 5 mice x 22 viruses), all but three mice seroconverted.
The three mice that did not seroconvert included one mouse from each group: reassortant 27
group, reassortant 83 group and reassortant 115 group (Table 2.5).
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Table 2.5

HI titers from FLUAV infected mice collected 14 days postinfection

Virus Name
7
10
22
23
27
31
55
63
71
75
83
87
95
99
107
109
111
115
126
Control
CA09
GD06
GD06×PR8

Collected
(DPI)a
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14

NO.1
80
80
80
40
20
80
80
80
80
80
<10
80
160
40
80
80
160
40
40
<10
40
20
80

Hemagglutination inhibitionb titer (by mice number)
NO.2
NO.3
NO.4
NO.5
40
80
40
80
80
80
160
160
80
40
80
40
80
80
40
80
10
40
20
20
40
80
20
80
80
80
80
160
160
80
160
160
40
80
40
80
80
80
40
40
80
80
40
40
80
80
160
160
80
160
80
160
40
40
40
40
40
40
40
40
160
80
80
80
160
160
160
80
<10
20
40
40
40
80
80
80
<10
<10
<10
<10
80
20
20
20
20
20
20
20
40
40
40
160

Mice were intranasally inoculated with 106 TCID50 of viruses as identified above. Sera was
collected at 14 DPI. Seroconversion was defined as HI titers > 1:20. a DPI, day post inoculation. b
Hemagglutination inhibition assays (HI) were conducted using 0.5% turkey red blood cells.
Reassortant 109 replicated efficiently in mammalian cells
To characterize the growth phenotype of viruses, we conducted virus growth kinetic
experiments in vitro. We infected canine kidney cells (MDCK) and human lung epithelial cells
(A549) with reassortant 109, CA09 or GD06 at an MOI of 0.001. In MDCK cells, all three
viruses replicated efficiently (Figure 2.4A). The maximum titers in MDCK cells were 7.81 (±
0.54), 7.27 (± 0.37), and 6.20 (± 0.17) log10TCID50/mL for reassortant 109, CA09 and GD06,
respectively. There was limited viral replication in A549 cells with maximum titers of 4.86 (±
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0.29), 3.97 (± 0.25) and 2.4 (± 0.06) log10TCID50/mL for CA09, reassortant 109 and GD06,
respectively (Figure 2.4B). The maximum replication titer in A549 cells for all three viruses
occurred at 48 hpi.
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Figure 2.4

Growth kinetics of viruses

The growth kinetics of each virus shown were characterized in MDCK cells (A) or A549 cells
(B) at an MOI of 0.001. Virus titers are expressed as mean ± standard deviation of three
independent experiments. The limit of virus detection was 100.699 TCID50/ml.
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GD06 showed limited transmission in ferrets
To determine the transmissibility of GD06 through direct contact, we anesthetized and
intranasally inoculated three ferrets each with GD06. One day later, we paired three naïve ferrets
to cages housing GD06 inoculated ferrets. The three GD06 inoculated ferrets shed virus at titers
of 3.93–5.032 log10TCID50/mL (Figure 2.5A) and the naïve ferrets shed virus at titers of 0.699–
5.366 log10TCID50/mL (Figure 2.5B). We were unable to detect viral titer in the direct contact
ferret in pair 1 (Figure 2.5B). At 5dpi, virus inoculated ferrets in pairs 1 and 2 of the direct
transmission treatment group were humanely euthanized and tissues sampled to evaluate viral
titers and pathology. At 21dpi the remaining GD06 inoculated ferret showed seroconversion (HI
titer of 1:640) (Table 2.6). The ferrets in direct contact pairs 2 and 3 seroconverted (HI titer of
1:640-1:1280). The ferret in pair 1 did not seroconvert (HI titer of 1:<10).
To determine the aerosol transmission ability of GD06 wild type, we intranasally
inoculated three ferrets. One day later, we placed three naïve ferrets in cages adjacent to the
infected ferrets. At 3 and 5 dpi, the infected ferrets shed virus at titers of 4.366–5.032
log10TCID50/mL (Figure 2.5C). Virus was not detected in naive ferrets (Figure 2.5D). At 21 dpi,
all inoculated ferrets had seroconverted (Table 2.6). HI titers ranged from 1:320 to 1:1280 for
GD06 infected ferrets and from 1:640 to 1:1280 for reassortant 109 infected ferrets. Serum
collected from all naïve ferrets was negative for the corresponding viruses (Table 2.6).
Reassortant 109 transmitted through direct contact
When we evaluated the transmissibility of reassortant 109, the inoculated ferrets shed
virus at titers of 4.866–6.199 log10TCID50/mL at 3 and 5 dpi (Figure 2.5E) and the three naïve
exposed ferrets shed virus at titers of 0.699–6.032 log10TCID50/mL (Figure 2.5F). At 5dpi, virus
inoculated ferrets in pairs 1 and 2 of the direct transmission group were humanely euthanized to
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evaluate viral titers and tissue pathology. At 21dpi serum the remaining inoculated ferret showed
seroconversion (HI titer of 1:2560) (Table 2.6) and all three direct contact ferrets seroconverted
(HI titers of 1:640–1:2560). These results suggested that reassortant 109 maintained its ability to
transmit by contact in ferrets. When we evaluated the aerosol transmission ability of reassortant
109, we found that even though the infected ferrets shed virus at titers of 4.032–5.366
log10TCID50/ml at 3 and 5 dpi (Figure 2.5G), there was no virus was detected in naive ferrets
(Figure 2.5H). Furthermore, at 21 dpi, all inoculated ferrets had seroconverted and HI titers
ranged from 1:640 to 1:1280 for reassortant 109–infected ferrets (Table 2.6) whereas all serum
collected from all naïve ferrets were negative for the corresponding viruses (Table 2.6).
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Figure 2.5

Viral titers from nasal wash fluids of ferrets

Ferrets were inoculated with 106 TCID50/ml of GD06 virus (A,C) or reassortant virus 109 (E,G). Naïve ferrets were
exposed either by direct contact with GD06 inoculated ferrets (B) or by aerosol contact with GD06 infected ferrets
(D). The same scheme was followed for reassortant 109 with naïve ferrets exposed by direct contact (F) or by
aerosol exposure (H). Nasal wash fluids that were collected on 3, 5, 7, and 10 dpi from ferrets and titrated in MDCK
cells. Ending titers are expressed as log10TCID50/ml. The limit of virus detection was 100.699 TCID50/ml.
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Table 2.6

HI titers from ferrets inoculated or exposed to GD06 or R109

Hemagglutination inhibition titer
Virus, experiment
groupa
Ferret 1
Ferret. 2
Ferret 3
GD06
Aerosol
Inoculated ferret
320
1,280
1,280
Exposed ferret
<10
<10
–c
Direct Contact
Inoculated ferret
–
–
640
Exposed ferret
<10
640
1,280
Reassortant 109
Aerosol
Inoculated ferret
640
1,280
1,280
Exposed ferret
<10
<10
–
Direct Contact
Inoculated ferret
–
–
2,560
Exposed ferret
2,560
640
1,280
PBS control
–
–
<10
a
FLUAV-inoculated ferrets were intranasally inoculated with 106 TCID50 per ml of virus; control
ferrets were inoculated with 1 ml of PBS; bSerum samples were collected at 21 days
postinoculation, and HI titers were determined using 0.5% turkey erythrocytes; cthe
hemagglutination inhibition titer was not available because the ferret was euthanized.
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GD06 and reassortant 109 were pathogenic in ferrets
To detect pathogenicity of GD06 and reassortant 109 in ferrets, we collected nasal
turbinate, trachea, and lung tissues of the humanely euthanized direct contact ferrets for titration
and histopathology. GD06 was detected only in nasal turbinate (virus titer of 3.199–3.699
log10TCID50/g/mL) (Figure 2.6). Reassortant 109 was detected in both nasal turbinate and
trachea tissues to a titer of 3.032–5.032 log10TCID50/g/mL. No virus was detected from lung
tissues. Ferrets inoculated with PBS showed no virus replication.

Figure 2.6

Viral titers from ferret tissues

Ferrets were inoculated with 106 TCID50/ml of GD06 virus, reassortant virus 109 or PBS
Control. At 5 dpi they were humanely euthanized and tissues collected from nasal turbinate,
trachea and lungs. Tissues were homogenized and then titrated in MDCK cells. The limit of virus
detection was 100.699 TCID50/ml. No virus was detected in the lungs. Reassortant 109 replicated
in nasal turbinate and trachea tissues, whereas GD06 was detected only in the nasal turbinates.
One ferret inoculated with GD06 and both ferrets inoculated with reassortant 109 had
evidence of moderate lymphoplasmacellular rhinitis with loss of cilia and multifocal replacement
of normal respiratory epithelium by stratified squamous epithelium (Figure 2.7). The other GD06
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wild type virus-inoculated ferret was minimally affected. No significant lesions were observed in
the tracheas of any ferrets. In addition, one of the ferrets inoculated with reassortant 109 had
mild focal lymphoplasmacellular peribronchitis and peribronchiolitis that extended slightly into
the adjacent lung. Fever (>40℃) was not present in any of the ferrets and there was minimal
body weight variation (data not shown).

Figure 2.7

Histopathology of ferret nasal turbinates, trachea and lung tissues

Ferrets were inoculated with 106 TCID50/ml of GD06 virus, reassortant 109 or PBS Control. At 5 dpi they
were euthanized and tissues collected from nasal turbinate, trachea and lungs. One GD06 infected ferret
had moderate turbinate pathology (rhinitis with moderate lamina proprial lymphoplasmacellular infiltrates
and loss of cilia or replacement of respiratory mucosal epithelium by stratified squamous epithelium),
whereas the other had minimal pathology (minimal lamina proprial lymphoplasmacellular infiltrates).
Both reassortant 109 infected ferrets had moderate to severe turbinate pathology, including
lymphoplasmacellular rhinitis and loss of cilia or replacement of normal mucosal epithelium by stratified
squamous epithelium. No significant lesions were seen in the trachea of any of the ferrets. There was
mild lung pathology in one ferret infected with reassortant 109 including peribronchitis and
peribronchiolitis. Overall, more pathology was observed in R109 than GD06 infected ferrets.

Discussion
CIV-H3N2 has become enzootic within the canine population since it was first isolated in
the early 2000s. It has also shown interspecies transmission to other companion animals,
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including cats and ferrets, suggesting companion animals may serve an important role as
intermediate hosts for FLUAVs 278-280. Serological surveillance indicates individual dogs have
been infected with both pdmH1N1 and CIV-H3N2 viruses 187 and naturally occurring
reassortants between the two have been reported 209,210. Others have demonstrated that a
reassortment bearing the HA and NA genes from CIV-H3N2 and all other genes from pdmH1N1
replicated to high levels and produced significant pathologic lesions in canine tracheal tissues 194.
Additional study of CIV H3N2 reassortants in the dog may be elucidative; however, there is a
current halt on gain-of-function experiments by the U.S. Government.
In our study, antigenic analysis showed that GD06 only weakly cross-reacts with ferret
antisera raised against two of the representative human H3N2 FLUAVs tested. and crossreactivity was limited to A/Sydney/5/1997 (H3N2) and A/Nanchang/933/1995 (H3N2). Our
results suggest contemporary seasonal influenza viruses do not cross-react with the novel H3N2
canine influenza viruses. Repeat exposures to antigenically drifted H3N2 viruses may broaden
the serological response in humans, and human serological studies are required to confirm herd
immunity to GD06-like viruses.
To assess the potential risk of reassortment, we attempted to generate all GD06CA09
reassortants with the HA gene of GD06. We were able to successfully generate 51 (40%) of 127
reassortants, suggesting the gene segments from GD06 and CA09 have moderate genomic
compatibility. Consistent with this finding, RNP luciferase reporter assays suggested that
specific constellations of GD06 and CA09 genes may enhance viral replication when compared
to the wild-type parental viruses. All four RNP complex constellations that showed enhanced
luciferase activity contained the NP gene segment from GD06 and the PB1 gene segment from
CA09. All 19 high growth reassortant viruses contained the PB1 gene segment from CA09 and
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most (84%) also contained the CA09 PB2 gene segment. Others have described the important
role of the PA gene segment in maintaining the stability of CA09 281. However, our RNP data
and our high growth reassortant phenotypes showed fairly equal representation of the PA gene
segment from GD06 and CA09.
High in vitro growth of the 19 reassortants did not uniformly translate to efficient
replication in mice. One of the limitations of using mice as an influenza animal model is their
resistance to influenza infection. Therefore, mouse adapted influenza viruses are needed to
model influenza pathogenicity with some notable exceptions including HPAI H5N1, certain H7
subtypes, some LPAI and the 1918 and 2009 H1N1 pandemic strains 282. There is a greater
distribution of α2,3 sialic acid receptors than α2,6 throughout the respiratory tract of mice and
this may explain why human influenza strains generally do not replicate well in mice without
prior adaptation 282. Previous study showed a CIV-H3N2 virus was not detected in the
respiratory tract of mice after experimental infection and animals remained seronegative 283. This
finding is in contrast to our study. While not all viruses replicated robustly in mice, many
reassortants and the wild-type GD06 replicated in the respiratory tract and all but three
inoculated mice seroconverted at 14 dpi suggesting some level of growth. The discrepancies in
these data may lie in minor variations in the representative viruses used (the previous researchers
studied A/Canine/Korea/01/2007 (H3N2)).
Most of the reassortants that replicated efficiently in mice lungs contained more gene
segments from CA09 than GD06. The maximum replication in mice lungs by a reassortant was
achieved by reassortant 109, which contained only the HA and NP genes from GD06. Overall
there was minimal weight loss in most of the infected mice. The introduction of CA09-gene
segments may account for the > 5% body weight-loss observed in mice inoculated with
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reassortants 111, 109, and 55. These three reassortants all consisted of an identical RNA
polymerase complex of PB2-CA09, PB1-CA09 and PA-CA09. However, other reassortants with
the same RNA polymerase complex did not cause weight loss >5%, suggesting other factors are
also important.
Compared to GD06, reassortant 109 showed enhanced replication in vitro and in vivo
experiments and maintained at least the same level of contact transmissibility between ferrets. In
another study, CIV-H3N2 replicated efficiently in the upper and lower respiratory tracts of
ferrets, and the animals exhibited clinical signs of disease, such as lethargy, sneezing, unkept fur,
and loss of appetite 284. In our study, the ferrets showed no clinical signs of illness possibly
related to a lower dose of virus used. In our hands neither GD06 nor reassortant 109 was detected
in ferret lung tissues, although there was mild lung pathology seen in one ferret infected with
109. Both viruses effectively replicated in nasal turbinate tissues, and reassortant 109 also
replicated in tracheal tissues.
Ferrets in our study infected with GD06 or reassortant 109 at 106 TCID50 shed virus at
titers of 4.032–6.199 log10TCID50/mL at 3 or 5 dpi. These titers are higher than those reported
previously in ferrets inoculated with A/canine/Korea/01/2007(H3N2) at 103.5 EID50 283. In
another study, ferrets with direct exposure to inoculated ferrets shed detectable virus at a mean
titer of 2.5–2.8 logEID50/ml from 10 to 11 dpi, and 2 of 3 exposed ferrets seroconverted 278. In
our study, direct exposure ferrets shed virus at titers of 0.699–5.366 log10TCID50/mL on 3, 5, and
7 dpi. Furthermore, all ferrets in direct contact with those inoculated with reassortant 109
seroconverted at 21 dpi. These findings suggest that, in ferrets, CIV-H3N2 and reassortant 109
have achieved relatively high replication efficiency and the ability to transmit via direct contact.
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In conclusion, reassortants between GD06 and CA09 showed increased viral lung titers in
mice and more pathological lesions in ferrets than wild-type GD06. These reassortants warrant
the use of enhanced CIV surveillance in the canine population, especially surveillance for
reassortant viruses with zoonotic potential.
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CHAPTER III
SEROLOGIC INVESTIGATION OF EXPOSURE TO INFLUENZA A VIRUSES IN
SHELTER-OWNED DOGS IN MISSISSIPPI

Sherry L. Blackmon, Kristina Hubbard, David R. Smith, and Xiu-Feng Wan
The work of this chapter is in preparation for publication
Abstract
Two emerging influenza A virus (FLUAV) subtypes circulate in the dog population:
equine origin canine influenza virus H3N8 (CIV-H3N8) and avian-origin CIV-H3N2. CIVH3N8 has been present in the U.S. at least as early as 1999, whereas CIV-H3N2 was introduced
to the U.S. in 2015 from Asia. Outbreaks and serological evidence suggest dog populations
having close contact with other dogs, such as dogs housed in shelters and boarding kennels, are
at increased risk for CIV infection. To date, there is no characterization of FLUAV
seroprevalence in shelter dogs in Mississippi. In our seroepidemiologic study of 565 dogs
randomly sampled during 2016-2017 from eighteen shelters geographically distributed statewide,
we identified 7/565 dogs (1.2%) that were potentially ELISA positive (S/N < 0.70) for exposure
to FLUAV. However, HI assay against selected canine, human, swine and avian FLUAV
revealed no detectible HI titer against the representative viruses tested. Our results suggest
Mississippi shelter dogs have had minimal exposure to FLUAVs.
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Introduction
Dogs warrant special consideration as FLUAV hosts due to their susceptibility to avian
and mammalian FLUAV and because they may act as “mixing vessels” for creating reassortant
viruses 194-196 with pandemic potential. Both α2,3 and α2,6 sialic acid receptors have been
identified in the canine respiratory tract, although predominantly α2,3 87,175,197,198. Serological
evidence as early as the 1970s suggests dogs can be infected with human strains of H1N1 and
H3N2 136,205 and more recent evidence also shows dogs seropositive for seasonal H3N2 and
pdmH1N1 180,206,270. Dogs have served as spillover hosts for many influenza strains, including
avian strains H5N1 201, H5N2 202, H9N2 203, and H10N8 204. Reassortant viruses consisting of
CIVxpH1N1, CIVxH5N2, CIVxSIV-H1N1 and CIVxH9N2 have been identified 195,200,209-211.
Dogs also have a large global population with a recent global estimate at ~700 million 199
including an estimated 80 million dogs in the U.S. 285. Compared to livestock and other FLUAV
species, dogs have much closer contact with humans. The public health implications of FLUAV
in dogs necessitates continued surveillance of this unique host.
Two CIV subtypes circulate in the canine population: CIV-H3N2 and CIV-H3N8. CIVH3N8 was identified in 2004 in greyhound racing dogs in Florida 137; however, retroactive
serological data suggest infection as early as 1999 174. In the U.S., CIV-H3N8 spread across the
country with high levels in 2005 until it was mostly undetected by 2014. Sera collected in 2005 –
2009 from shelter and family owned animals (n=1,268) from 42 states with influenza-like illness
determined the overall seroprevalence of CIV-H3N8 to be 49% 177. Another large study of sera
from shelter dogs (n=5,160) sampled during years 2009 – 2012 showed CIV-H3N8
seroprevalence was decreasing across the U.S. with 10% seroprevalence in Colorado, 8.5% in
New York and 0% in South Carolina, Florida, California, Texas 179. The most recent large study
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from sera collected in 2012 – 2014 from pet dogs (n=1,082) presenting for preventative care and
elective surgery showed seroprevalence of CIV-H3N8 was only 2.3% 180. In that study,
seroprevalence was higher against human H1N1 and H3N2 at 4% and 2.4%, respectively 181.
Collectively, data suggests CIV-H3N8 has been rarely identified since 2016 182.
CIV-H3N2 was first identified in 2006 in Korea and China and later detected in Thailand and
other areas of Southeast Asia 183-189. Naturally occurring reasssortant CIV-H3N2 strains have
been isolated from dogs in Asia and recent suggests reassortant CIV-H3N2 may pose a public
health risk 195,200,209-211,256. The first CIV-H3N2 epizootic outside of Asia occurred in the Chicago
area of the U.S. in late February 2015 and was characterized by mild to moderate respiratory
disease and low mortality that affected over 1000 dogs and spread to 23 additional states within 5
months 190. Serological evidence suggests CIV-H3N2, like CIV-H3N8, currently circulates at
very low levels in the U.S. Sera collected from April – August 2015 from dogs (n=451)
presenting at veterinary teaching hospital located near the initial outbreak showed seroprevalence
for CIV-H3N2 was 2.21% by HI assay. During the ~ 14 years since CIV was first identified in
the U.S., at least one, if not both, subtypes have been reported in 46 of the 48 contiguous states in
the U.S. 286; however, at the population level, CIV is characterized by short-lived outbreaks and
hotspots, mostly in large, urban animal shelters 182. However, FLUAV exposure in shelter dogs
in Mississippi is unknown. The objectives of this study were to determine 1) the seroprevalence
of FLUAV antibodies in the Mississippi shelter dog population; 2) the diversity of FLUAV
subtypes in this population; 3) risk factors associated with a positive serologic test result.

73

Materials and Methods
Sera collection from shelter dogs
Whole blood samples were collected as previously described (1). Briefly, blood was
collected from a random sample of 571 shelter-owned dogs (> 8 weeks of age) from 18
participating shelters located within nine geographically distributed Mississippi Department of
Health public health districts from 2016-2017 (Figure 3.1). The number of dogs sampled within
each public health district was proportional to the total shelter dog population housed within that
district. The total shelter dog population was previously estimated from a statewide census of
animal shelters. For example, 10% of dogs identified in the census were housed in public health
district one, therefore 10% of the blood samples were collected from shelters in district one. The
following data was recorded at the time of blood collection by a licensed veterinarian: estimated
age based (Figure 3.2), breed (as best as could be determined) and the corresponding American
Kennel Club breed group (Figure 3.3), shelter intake date, blood collection date, weight (kg)
(Figure 3.4), and body condition score (BSC, 1-9). After sample collection the serum was
separated and stored at -80C until further use.
Antibody detection with ELISA
Available sera (n=565) were screened using a multispecies, commercially available
competitive enzyme-linked immunosorbent assay (ELISA) (IDEXX, Westbrook, ME) that
detects a decrease in optical density if antibodies in the sera sample bind the FLUAV-NP protein
coated plate. The ELISA was performed following the manufacturer’s standard protocol.
Briefly, 15 µl of the serum sample was diluted in 135 µl of sample diluent provided in the kit and
100 µl of each diluted sample, undiluted negative control and undiluted positive control were
dispensed into the provided antigen plate in triplicate. The plate was incubated at room74

temperature for 60 minutes, followed by washing three times with working strength wash buffer.
Next, 100 µl of anti-influenza A monoclonal antibody enzyme conjugate was added to each well
and incubated for 30 minutes at room-temperature, followed by repeated washing. Next, TMB
substrate solution was dispensed into each well and incubated at room-temperature for 15
minutes. Finally, 100 µl of stop solution was added to each well. The optical density (OD) was
measured at 650 nm using a plate reader (Cytation 5, BioTek Instruments, Inc., Winooski, VT).
All plates met the validity criteria set by the manufacturer, i.e. the manufacturer provided
negative control OD values were > 0.60 and the mean S/N of the manufacturer provided positive
controls were <0.50. The samples were analyzed by the OD value of the sample divided by the
OD value of the negative control to obtain sample-to-negative (S/N) ratio. Because we did not
have the capability of optimizing the ELISA kit for use with canine sera to determine the S/N
cutoff that would allow the best sensitivity and specificity, we relied on the S/N cutoff values
referenced by the manufacturer for use in mammalian sera and in the literature 157,287,288. The
manufacturer did not provide sensitivity and specificity information for use with canine sera;
however, their literature shows that 100% of dogs (n=8) tested ELISA positive by 32 days post
inoculation 289. We classified ELISA S/N ratio < 0.60 as positive and S/N ratio range of (>0.60 < 0.70) as suspect positive. A S/N ratio of > 0.70 is likely FLUAV antibody negative. The color
development is inversely proportional to the amount of FLUAV antibodies in the test sample.
Antibody detection with HI Assay
To determine CIV exposure in Mississippi shelter dogs, the collected sera was tested
against two canine influenza viruses by HI assay. Influenza A/canine/Guangdong/1/2006(H3N2),
one of the earliest CIV strains isolated from dogs in southern China 183, was propagated in 9- to
11-day-old specific pathogen free (SPF) embryonated chicken eggs. Influenza
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A/canine/Iowa/13628/2005(H3N8) was maintained in our laboratory and propagated in MDCK
cells (American Type Culture Collection, Manassas, VA). In addition to HI testing against two
representative strains of two CIV subtypes, additional viruses isolated from human, swine and
avian hosts were also tested to determine if shelter dogs had been exposed to diverse strains of
FLUAV. These viruses are listed in Table 3.3. HI assay was performed as described in the WHO
protocol 290. Canine sera was pretreated with freshly reconstituted Vibrio cholerae receptor
destroying enzyme (Denka Seiken USA, Campbell, CA) in a ratio of 1: 3 (serum:RDE) in a 37°C
water bath for ~ 20 hours, followed by heat inactivation in a 56°C water bath for 30 minutes. Six
parts of PBS were added to the treated serum for a final serum dilution of 1:10. To perform the
HI, 50 ul of RDE treated sera was added to the first row of a 96-well, V-shaped microtiter plate,
followed by adding 25 μl of PBS to all remaining wells and 25 μl was transferred from the first
row to each successive row to generate a two-fold serial dilution of sera. Diluted sera were
incubated with 4 HAU per 25 μl of CIV at room temperature for 30 minutes. Finally, 50 µl of
freshly prepared 0.5% turkey red blood cells were added to each well, followed by incubation at
room temperature for 30-45 minutes, reading the plate when the PBS-RBC negative control
“pellet” fully settled. All samples were tested in triplicate for the determination of end-point
antibody titers. One well served as a positive control with ferret generated antisera against the
testing virus and the last well served as a PBS-RBC control. For HI testing, the sera samples
were divided into three groups (A, B, and C) based on ELISA results. Group A included all sera
(n=565) and all sera were HI tested against the two CIV strains identified in Table 3.3. Group B
was limited to sera with ELISA S/N ratio of < 0.60 (i.e. sera 99, 238 and 543) and were subject
to HI testing against additional viruses (Table 3.3). Group C was limited to sera samples with
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ELISA S/N ratio in the range of >0.60 - < 0.70 (i.e. sera 259, 219, 348, 567) and were HI tested
against a panel of human viruses (Table 3.3).
Results
Of the 571 dogs sampled statewide, 41% were puppies less than one year of age, 40%
were young adults from one to three years of age and the remaining dogs sampled were older or
the age was unrecorded (Figure 3.2). From this group of 571 dogs, serum from 565 dogs was
tested using a commercial competitive ELISA kit (IDEXX, Westbrook, ME), a colorimetric
assay that detects IgG antibodies bound to a highly conserved epitope of the NP protein of
FLUAV. Samples with a sample-to-negative (S/N) ratio were classified as follows: < 0.60
(positive); > 0.60 - < 0.70 (suspect positive); > 0.70 (negative). Based upon these criteria, we
identified three likely positive samples and four suspect positive samples (Figure 3.5, see also
Appendix A). Serum obtained from dog 99 was strongly positive with a S/N ratio of 0.28 (+ 0.03
SD of average of three replicates). Dog 99 was a Shepherd mix breed approximately four months
of age and 13kg at the time of sera collection in July 2016. Another sample, from dog 238, was
weakly positive with an S/N ratio of 0.58 (+ 0.05 SD). Dog 238, a 22kg Boxer mix
approximately 1.5-year-old at the time of sera collection in August 2016, had a shelter intake
date only one day before serum collection. Dog 543, an approximately 1.5-year-old Hound mix
of unknown weight, was at the threshold with a S/N ratio of 0.6 (+0.01 SD). Dogs 99, 238 and
543 were all housed at different shelters located within different public health districts (PHD),
i.e. shelters 4, 9 and 17 in PHD 4, 1, and 9, respectively. Five of the samples (Group C) had a
S/N ratio in the suspect range of < 0.60 - < 0.70 and these samples were collected from shelters
9,7,11 and 18 from PHD 1,3,5 and 9, respectively. All other samples had an S/N ratio > 0.70
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(Figure 3.5, see also Appendix A). Our ELISA results indicated a 1.2% (7/565) seroprevalence
for FLUAV in the Mississippi shelter-dog population.
Sera (n=565) were tested by HI assay against CIV-H3N2 and CIV-H3N8. The HI titer for
all samples was <1:10, the limit of detection (LOD) for the assay. The homologous titers for
ferret generated antisera to CIV-H3N2 and CIV-H3N8 were 1:640 and 1:320, respectively.
Additional HI tests against diverse human, swine and avian viruses were performed on the sera
from dogs 99, 238 and 543 (Group B) based upon the ELISA results. The HI titer for these three
samples was also <1:10 (LOD). Finally, five sera samples (Group C) with a S/N ratio in the
suspect range of < 0.60 - < 0.70 (Table 3.3) were HI tested against human influenza viruses but
these samples also had undetectable HI titers <1:10.
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Figure 3.1

Mississippi Department of Health Public Health Districts (2016-2017)

Samples were collected from 571 shelter-owned dogs across nine geographically distributed
Mississippi Department of Health public health districts from 2016-2017. Image Source:
https://msdh.ms.gov/msdhsite/_static/resources/5714.pdf
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Figure 3.2

Age Distribution of Shelter Dogs

The majority (41%) of the dogs sampled were puppies (less than 1 year of age) and 40% were
between 1-3 years of age. Age is estimated by dentition and most reliable for dogs 6 months and
younger.

80

200
180

NUMBER OF DOGS

160
140
120
100
80
60
40
20
0

Figure 3.3

American Kennel Club (AKC) breed distribution of sampled shelter dogs

Breed information of shelter dogs is usually unknown and dogs in our sample were assumed to
be mixed breeds. Veterinarians and support staff used their expertise to classify these mixed
breed dogs into breed groups recognized by the AKC. However, some animals could not be
classified and were labeled as unknown. Sporting dogs (n=188) were most represented as this
group includes Labrador Retrievers, a common breed in Mississippi. Terrier (n=104) was the
second most represented group and includes breeds such as the Staffordshire Terrier and others
commonly referred to as Pit Bulls.
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Figure 3.4

Weight distribution of sampled shelter dogs

The dogs’ weights were recorded at the time of sera collection when available. The lower
weights, i.e. 1-10kg, are indicative of a large puppy population.

82

Figure 3.5

ELISA Results (S/N frequency distribution)

Sera collected from shelter dogs (n=565) were tested using a competitive ELISA.
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Table 3.2

Viruses used for HI testing canine sera

Virus
A/canine/Guangdong/1/2006
A/canine/Iowa/13628/2005
A/California/04/2009
A/Switzerland/9715293/2013
A/Hong Kong/4801/2014
A/swine/Texas/A01104013/2012
A/swine/Ohio/09SW96/2009
A/swine/Iowa/15/2013
A/swine/Iowa/19/2013
A/swine/Indiana/13TOSU1154/2013
A/mallard/Wisconsin/A00751454/2009
A/mallard/Oregon/A0030758/2007
A/mallard/Wisconsin/A00661712/2009
A/mallard/Washington/A00714770/2009
A/mallard/Wisconsin/10os3845/2010
A/mallard/Oregon/A00571208/2007
A/American black
duck/Delaware/A00870108/2010
A/northern shoveler/Illinois/10OS3632/2010
A/mallard/Minnesota/10os4670/2010
A/mallard/South Dakota/A00536114/2007
A/mallard/Illinois/10OS3249/2010
A/bufflehead/Wisconsin/10OS3204/2010
A/hooded merganser/New
Brunswick/03750/2009
A/long-tailed duck/Wisconsin/10OS3912/2010

Sera testedb

Antigenic
group
H3N2
H3N8
H1 2009p
H3N2
H3N2
H3N2
H3N2-α
H1 δ1
H1 δ2
H1N1- γ
H1N1
H2N3
H3N2
H4N6
H5N2
H6N1
H7N3

Source of virus
canine
canine
human
human
human
feral swine
domestic swine
domestic swine
domestic swine
domestic swine
avian
avian
avian
avian
avian
avian
avian

A
A
B, C
B, C
B, C
B
B
B
B
B
B
B
B
B
B
B
B

H8N4
H9N2
H10N7
H11N2
H12N5
H13N6

avian
avian
avian
avian
avian
avian

B
B
B
B
B
B

H14N6

avian

B

a

a

The host from which the virus was isolated
Group tested: A) All sera (n=565 dogs); B) Sera with S/N < 0.60 and includes dogs 99, 238 and
543; C) Sera with S/N >0.60 to < 0.70 and includes dogs 259, 219, 348 and 567
b

Discussion
This is the first characterization of FLUAV exposure in the shelter dog population in
Mississippi and suggests minimal exposure in this population. Of the 565 samples ELISA tested,
one sample was strongly positive, one sample was weakly positive, and one sample was at the
threshold. Four additional samples were in the suspect range of a positive result. None of the 565
samples had a detectable HI titer against CIV-H3N2 or CIV-H3N8. It is possible for a serum
sample to be ELISA positive and HI negative because ELISA can detect IgG to any FLUAV
based on the highly conserved NP protein, whereas HI assay detects antibodies specific to the
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HA antigen of the testing virus, although cross-reactivity to other closely related viruses is
possible. One recent report of FLUAV seroprevalence in dogs located primarily in the Midwest
U.S. during the time of the CIV-H3N2 outbreak identified 16/453 (3.5%) seropositive samples
using an IDEXX Influenza A Ab ELISA kit, however no information was provided regarding the
cut-off value for a positive result. This same study identified a 10/453 (2.2%) seropositivity on
HI assay (against CIV-H3N2, strain unidentified) using a titer of 1:32 as a cutoff and only six
samples were both ELISA and HI positive.
Although competitive ELISA is a robust and rapid assay for testing a large number of
samples, one limitation of its use is the need to perform a receiver operating characteristic (ROC)
curve analysis applicable to the host species and ELISA kit to be used. ROC analysis aids in the
determination of the S/N cutoff value that optimizes sensitivity and specificity. However, ROC
analysis requires a comparison to a gold standard test, usually an HI assay. It also requires
animal groups assigned to negative exposure, inoculated and sometimes includes vaccinated
animals as the ELISA assay may perform differently in these exposure groups. Unfortunately,
we did not have access to canine sera collected under these conditions. For some species, i.e.
horses, pigs and several avian species, this data is available from the manufacturer and/or
literature reports providing a comparison of the sensitivity and specificity across multiple
commercially available kits 287,288. However, data applicable for use with canine sera is very
limited. The IDEXX Influenza A Ab ELISA kit (#99-53101) is validated for detecting avian,
swine and equine influenza in those species, with literature supporting the detection of CIVH3N8 in 3/8, 7/8 and 8/8 dogs at 18, 25 and 32 dpi, respectively; however, this kit is only
available outside of the U.S. 291,292. The IDEXX AI MultiS-Screen Ab Test (#99-12119) is
available in the U.S. and was used in this study and does not provide supporting documentation
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for use with canine sera, although communication with the manufacturer suggests the reagents in
the two kits are essentially the same 288. Another limitation of ELISA regardless of manufacturer
is the post-exposure time lag before ELISA can detect positive serological status. This is a
consideration whenever a sample is HI positive and ELISA negative because HI assay can detect
the earlier responding IgM, sometimes as early as 5dpi, a time when ELISA sensitivity is poor
293

. Although none of our samples were HI positive/ELISA negative, ELISA testing soon after

shelter intake date may fail to detect recently infected dogs.
Sera from dog 99 was strongly ELISA positive and we hoped to identify the subtype of
FLUAV to which this dog may have been exposed. However, dog 99 was HI negative against all
representative FLUAVs we tested. HI testing against circulating viruses in Mississippi during the
Spring/Summer of 2016 along with additional viruses including the WHO reference panel for
subtyping by HI may have allowed us to subtype this strongly ELISA positive sample; however,
there were limitations in the amount of serum available. The HI assay is considered the
WHO/OIE test of choice for serological diagnosis of FLUAV in animals and standard protocols
have been developed for birds, pigs, horses and humans; however, no standard protocol exists for
canine influenza surveillance 290,294,295. Therefore, another limitation of the HI assay is the need
to optimize pretreatment of the testing sera which may have species specific inhibitors to the
RBCs used downstream in the assay and to identify the best species of RBC to use against the
virus of interest. Others have published an optimized protocol for CIV HI assay with respect to
RDE pretreatment of canine sera and using 0.5% turkey red blood cells against CIV-H3N8 294.
The ROC analysis results determined that a HI antibody titer of 1:32 for a seropositive test result
optimized sensitivity and specificity against CIV-H3N8.

86

Another limitation of the HI assay is that HI titers decrease as circulating viruses undergo
significant antigenic change from the testing virus 296. CIV-H3N8 and CIV-H3N2 are considered
antigenically stable, or at least stable when compared to swine and human H3N2s FLUAVs, but
recent evidence suggests selective pressure on CIV-H3N2 has resulted in antigenic variation. In a
recent study of 399 tracheal swabs collected from dogs with respiratory disease in China, 54
CIV-H3N2 viruses were isolated, including 41 isolated after 2016. Beginning in early to mid2016, all CIV-H3N2 isolates in this study have four amino acid substitutions: 251R and 590S in
the PB2 protein and 146S and 242I in the HA protein which have also been identified in human
viruses 297. These isolates show HI titers in the low range (i.e. 40-80) when tested against
antisera generated with several 2009 strains 297. It is unclear if this new clade originated from the
U.S. or South Korea 297. Furthermore, even during the short time CIV-H3N2 spread in the U.S.,
strains showed lineage-defining amino acid changes with potential for phenotypic change. These
changes included in the HA protein at position 219 near the receptor binding site and another at
antigenic site 188 and also in the NA protein at 155 and 222, near the enzymatic cleavage site,
among others 193. Performing HI assay against CIV-H3N2 will require more careful selection of
testing viruses. Studies comparing the pathogenicity, transmission, and seroconversion between
different CIV-H3N2 strains, including A/Canine/IL/41915/2015 and
A/Canine/Korea/CY009/2010 are in progress 298.
Previous studies suggested the likelihood of CIV-H3N8 seropositivity in the U.S. was
associated with geographic region (southeast during 2005, west and northeast during 2006 and
2007, and northeast during 2008) and exposure setting (dogs housed in shelters or boarding
kennels during 2005 and 2006) 177. CIV-H3N8 circulation peaked ~ 2007, steadily decreased and
has been rarely seen since 2016

182

. Since 2015, CIV-H3N2 has been the primary source of
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outbreaks in the U.S., in urban locations including Chicago and Atlanta, and most recently in
major West Coast cities. As of July, 2019 the current CIV-H3N2 outbreak areas in the U.S. are
in urban areas of California including Northern (San Francisco Bay Area), Southern (Los
Angeles), Central (Sacramento) and Portland, Oregon 299. The West Coast of the U.S. is a major
transportation hub for air travel to Asia and phylogenetic analysis has traced at least three CIVH3N2 outbreaks in the U.S. to separate introductions from Asia 193. These outbreaks include the
original introduction in 2015 in Chicago, an early 2017 outbreak in Los Angeles traced to dogs
imported from China and an outbreak in Atlanta in May 2017 that likely originated from Korea
193

. Four clusters of CIV-H3N2 were reported in Ontario, Canada in early 2018 300. The source

of these introductions is unknown, but animal welfare organizations have rescued large numbers
of farmed dogs from Korea where CIV-H3N2 seroprevalence is relatively high at ~ 19% 188,193.
According to Humane Society International (HIS), “since 2015, we’ve permanently shut down
14 dog meat farms in South Korea and rescued nearly 1,800 dogs flown to the USA, UK, Canada
& Holland for adoption” 301.
These outbreaks suggest animal shelters, kennels and other facilities with high population
density, high inter-facility transfer rates and potential for dog-to-dog contact remain the main
source of CIV exposure for most dogs. The CIV vaccine is not a core vaccine but it is a
“lifestyle” vaccine and recommended for dogs who have contact with other dogs and shared
environments such as daycare, boarding facilities, shelters, etc. 302. CIV-H3N2 presents several
additional challenges in the shelter setting. The incubation period for CIV-H3N2 is 2-8 days
when dogs are most contagious but without clinical signs vs. only 1-5 days for CIV-H3N8 with
clinical signs in most cases appearing in 2-3 days 303. CIV-H3N2 is shed longer than CIV-H3N8,
at 3-4 weeks vs. <2 weeks, respectively, and up to 20% of infected dogs may be asymptomatic
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303 304,305

. Inter-facility transfers also increase the potential for CIV outbreaks. Data estimates

435,810 or ~ 25% of shelter animal intakes were transfers, with California reporting the highest
receiving rate and Mississippi reporting the highest transfers out at ~39% 306. Shelter guidelines
promote increasing transfer rates between shelters and rescue groups as an alternative to
euthanasia when shelter capacity is reached 307. Urban shelters frequently reach capacity and
transfer animals as needed to other nearby shelters and foster families in the local community.
Although this is the best option from an animal welfare perspective, it presents biosecurity
challenges. Although transfer rates are unknown, although the authors noted a limited
participation from shelters in the South and Midwest. Shelters in the Southeast participate in
transfers but usually transfer to other geographic regions with a greater number of adoptable
homes. Large foundations provide substantial financial support specifically for these transfers
from rural areas, including from Mississippi to the Northeast 308,309.
Evidence suggests CIV-H3N2 outbreaks occur more frequently in urban areas with more
international networks. Furthermore, as of July, 2019 there is no evidence of CIV-H3N2 in
owned dogs in MS as indicated by syndromic surveillance data generated by diagnostic samples
submitted by general practice veterinarians in MS 193,310. Our data suggest minimal CIV exposure
in the Mississippi shelter dog population; however, rural dog populations in the U.S. likely face
increased risk of FLUAV transmission from other species, especially pigs 200 and horses 137.
Transmission of pig FLUAV strains to dogs has important implications for public health and
surveillance of the canine host should continue. Additionally, greater resources are needed by
USDA-APHIS and the CDC to address the public health challenges of importing large groups of
rescued dogs.
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CHAPTER IV
PATHOGENICITY OF EMERGING INFLUENZA D VIRUS AND SWINE INFLUENZA A
VIRUS COINFECTION IN DOMESTIC PIGS

The work of this chapter is in preparation for publication.
Sherry Blackmon, Alicia K. Olivier, Xiaojian Zhang, Liyuan Liu, Minhui Guan, Mark
Crenshaw, Shengfa Liao, William Epperson, and Xiu-Feng Wan
Abstract
Swine influenza A virus (FLUAV) causes herd morbidity that may approach 100% but low
mortality. Influenza disease severity may worsen with bacterial coinfection; however, viral-viral
infections are not well understood. Emerging influenza D virus (FLUDV) was first identified in
pigs with respiratory disease. In FLUAV positive feral swine (n=96), 42% had antibodies to both
FLUAV and FLUDV, suggesting the host-pathogen ecology may include frequent coinfections
226

. Our data provide insight as to whether coinfection increases pathogenesis in swine compared

to infection of FLUDV or FLUAV alone. Influenza seronegative domestic swine (n=25) were
intranasally inoculated with swine FLUAV, FLUDV, FLUAV+FLUDV or sterile PBS. Pigs were
monitored for clinical signs and virus shedding and euthanized at 5dpi for virus quantification and
characterization of pathogenicity in respiratory tract tissues. Nasal shedding showed that in single
infections, 5/5 and 6/7 pigs shed FLUAV or FLUDV at 3, 4 and/or 5 dpi, respectively. In the
coinfection group 7/7 pigs shed FLUAV but only 1/7 shed FLUDV at 3, 4 and/or 5 dpi. In
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respiratory tract tissues, there was no difference in FLUAV viral copy number between the single
and coinfection groups (P>0.05); however, FLUDV viral copy number was higher in the turbinate
and soft palate of single infection group compared to the coinfection group (P<0.05).
Immunohistochemical analysis of cleaved caspase-3 (CC3), a downstream effector caspase and
important regulator of apoptosis, showed the mean number of CC3 positive cells was higher in the
FLUAV group (93 + 22 SEM; range: 47-174) than in the control group (19+ 3 SEM; range 12-27)
(P<0.05) but there were no differences in the FLUDV and COINF groups (P>0.05). Our findings
suggest simultaneous exposure coinfection does not alter nasal shedding or tissue viral load of
FLUAV but coinfection is associated with reduced nasal shedding and tissue viral load of FLUDV
infected pigs.
Introduction
Swine FLUAV is one of the top three health challenges facing the swine industry 149.
Although mortality is low, morbidity may approach 100%

148

. FLUDV, the most recently

identified emerging influenza, was first isolated in April 2011 from 15-week old pigs in
Oklahoma showing clinical signs consistent with influenza like illness 49. The pigs were qRTPCR negative for FLUAV, porcine reproductive and respiratory syndrome virus, porcine
coronavirus, and porcine circovirus. Electron microscopy revealed what appeared to be an
Orthomyxoviridae virus that was eventually classified as a separate genus. FLUDV shares
approximately 50% homology with FLUCV but doesn’t reassort with FLUCV or cross-react to
FLUCV antibodies 25,49.
FLUDV has now been identified in swine 49, bovids, 25, small ruminants, 214, camels 215
and horses 216, indicating it has a diverse host range similar to FLUAV, although it is more
closely related to FLUCV. FLUDV appears to be globally widespread and has been isolated
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and/or identified by serology in Mexico 217, Italy 218,219, France 220, Ireland 221, Luxembourg 222,
China 223,224, Japan 225, Kenya, Morocco, Togo and Benin 215. Because some studies have
estimated seroprevalence in bovids as high as 80%, bovids are the suspected reservoir of
FLUDV222. An early estimate of FLUDV seroprevalence in swine was 9.5% based on a sample
size of 220 pigs aged 3-20 weeks submitted to a diagnostic lab in Minnesota for unrelated
purposes 49. A larger study (n=3106) showed an 11.7% (364/3106) seroprevalence for FLUDV in
domestic swine in Italy, sampled at slaughter from June-December 2015. Our recently reported
data estimated ~ 19% seroprevalence of FLUDV in feral swine sera (n=256) collected in the U.S.
from October 2012 – September 2013 226 which is similar to seroprevalence reports in beef cattle
(13.5%–18.3%) 311.
Serological evidence suggests that FLUAV and FLUDV coinfection may play a role in
the ecology and epidemiology of influenza in feral swine 226 and transmission of emerging
diseases from wildlife, including bi-directional transmission of influenza between feral swine
and domestic swine, poses a biosecurity risk 255,287. In our previous study a small subset of feral
swine sera samples collected in the U.S. from 2010–2013, approximately 43% (41/96), were
seropositive for FLUDV and FLUAV, suggesting the host-pathogen ecology may include
coinfections 226. Coinfection may lead to viral-viral interactions (VVIs), or “any process by
which infection caused by one pathogen affects the probability, timing, or natural history of
infection by another” 232. Coinfection implies concurrent infection but must be distinguished
between single, sequential or multiple exposures and VVIs are broadly classified by three
outcomes: interference, enhancement, or accommodation and achieved by incredibly diverse
mechanisms depending on the virus genus 237,238. The objective of our study was to use a
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simultaneous exposure coinfection model to characterize the pathogenicity and tissue tropism of
FLUAV + FLUDV in domestic pigs.
Materials and Methods
Viruses and Cells
Animals were infected with D/bovine/C00046N/Mississippi/2014 (abbreviated as D/46N)
and/or A/swine/Texas/A01104013/2012 (H3N2) (abbreviated as SIV-H3N2) isolated from feral
swine. D/46N was isolated from sick cattle in Mississippi 311 and propagated in human rectal
tumor cells (HRT-18G) (American Type Culture Collection, Manassas, VA), whereas SIVH3N2 was isolated from feral swine 312 and propagated in MDCK cells (American Type Culture
Collection, Manassas, VA). Viruses were propagated in Opti-MEM I Reduced Serum Medium
(Thermo Fisher Scientific, Asheville, NC, USA) supplemented with 1 µg/mL of TPCK-trypsin
(Gibco, New York, USA) at 37°C under 5% CO2. The predominant exposure for swine in the
U.S. is the FLUAV H3 subtype and strains circulating in feral and domestic swine are
antigenically and genetically similar

155,157,255,312

. Because pathogenicity is strain, dose and

route dependent, we used swine FLUAV and FLUDV stains previously shown by our lab to
produce successful infection in pigs at 106 TCID50/mL by intranasal inoculation 226,313.
Animal study
Animal experiments were conducted under BSL-2 conditions in compliance with
protocols approved by the Institutional Animal Care and Use Committee of Mississippi State
University. Twenty five pigs (Large White x Landrace) aged 116-120 days with a mean weight
of 43 kg (range 24-62 kg) were provided by the Mississippi State University Department of
Animal and Dairy Sciences (MSU-ADS). The pigs were farrowed at MSU-ADS, were
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unvaccinated and biosecurity protocols were in place to limit contact with personnel or students
with self-reported clinical symptoms of respiratory infection as well other animals. All pigs were
housed together prior to the study. Five days prior to the start of the study, the pigs were
transferred to BSL-2 animal facilities for acclimatization. At - 8 days and repeated at 0 dpi, the
pigs were confirmed serologically negative by HI assay against the challenge viruses and other
representative influenza viruses (Figure 4.1). These viruses were chosen to represent the
antigenic strains in the vaccine used to vaccinate the sows (Flusure XP® Zoetis, USA) at 84 days
gestation as well as seasonal human influenza strains. The pigs tested seronegative against the
following viruses: D/bovine/C00046N/Mississippi/2014 virus (challenge virus); swine viruses
A/swine/Texas/A01104013/2012 (challenge virus), A/swine/Indiana/13TOSU1154/2013,
A/Swine/Iowa/15/2013 and A/swine/Ohio/09SW96/2009; and human viruses
A/HK/4801/2014(H3N2) and A/California/04/2009.
At 5 days prior to inoculation all pigs were transferred to BSL-2 facilities and assigned
by ear tag number to one of four treatment rooms (12x12 feet with negative air flow) as indicated
below. Although all pigs were 116-120 days old, their weight range was highly variable so they
were first stratified in groups of four of similar weights and then randomly assigned to one of
four infection treatment groups: influenza A virus (FLUAV) (n=5), influenza D virus (FLUDV)
(n=7), FLUAV + FLUDV (COINF) (n=7) or sterile PBS control (CTRL) (n=6). Investigators
and animal care personnel were not blinded to treatment groups and work flow was CTRL,
FLUDV, FLUAV and COINF. Pigs were anesthetized with TKX (Telazol® 4.4 mg/kg, ketamine
2.2 mg/kg, and xylazine 2.2 mg/kg) at 0.044 mL/kg and intranasally infected as follows: FLUAV
group received 106 TCID50/mL of A/swine/Texas/A01104013/2012 in a volume of 1 mL
administered in approximately equal doses to the right and left nostril by syringe; FLUDV group
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received 106 TCID50/mL of D/46N using the same method as above; COINF group received 106
TCID50/mL of A/swine/Texas/A01104013/2012 and 106 TCID50/mL of D/46N using the same
method as above; and CTRL group received only sterile PBS using the same method as above.
Because pathogenicity is strain, dose and route dependent, we used swine FLUAV and FLUDV
stains previously shown by our lab to produce successful infection in pigs at a smaller dose (106
TCID50/mL) and by intranasal inoculation 226,313. FLUAV H3 subtype is the predominant
influenza virus exposure in feral and domestic swine is subtype H3N2 155,157,255 and intranasal
inoculation simulates a more natural route of infection 314.
During the study, clinical signs, rectal temperatures, and nasal swabs were taken daily
and whole blood collected at 0, 3 and 5 dpi. At 5dpi all pigs were euthanized. The pigs were fully
anaesthetized with 0.044 mL/kg TKX and nasal swabs and blood collected immediately prior to
euthanasia by administration of a barbiturate solution (1 mL/4.5 kg body weight). Pigs were
necropsied and 14 respiratory tract tissues collected including: distal, middle and ethmoid
sections of nasal turbinate; soft palate; upper, middle and distal sections of trachea; bronchus;
and one section from each lung lobe (left cranial, left caudal, right cranial, right middle, right
accessory and right caudal). Tissues were fixed in 10% buffered formalin and additional sets
were frozen at -80C.
Clinical Data
To assess clinical signs of influenza infection, prior to entering the enclosure, pigs were
observed from a window for changes in attitude, elevated respiratory rate, cough, dyspnea, nasal
or ocular discharge or conjunctivitis. Rectal temperatures were obtained for all pigs beginning
three days prior to inoculation (-3 dpi) and daily through day 5 of the study (5 dpi) when animals
were euthanized. Rectal temperatures were taken without any sedation on -3dpi, -2dpi, -1dpi,
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1dpi, 2dpi, 3dpi, and 4dpi. Rectal temperatures were taken immediately after administration of
TKX on 0dpi and 5dpi. Nasal swabs were collected daily (0-5dpi) using a sterile cotton tipped
applicator and transported in sterile PBS supplemented with PenStrep (1:100 w/v) on ice to the
BSL-2 lab where they were aliquoted and stored at -80°C. Blood samples were taken at 0, 3 and
5 dpi and stored at 4C until a complete blood count (CBC) could be performed by the MSUCVM Diagnostic Lab. A CBC for each pig was obtained with the exception of blood samples
that clotted prior to processing which included one pig from the control group at 0dpi, one pig
from the FLUDV group at 0 dpi, one pig from coinfection group at 3 dpi and at 5dpi and one pig
from the FLUAV group at 5dpi.
Tissue homogenization
Respiratory tract tissues were collected at necropsy and frozen at -80°C until homogenization.
Tissues were thawed on ice and a sterile #10 blade and forceps were used to cut and then weigh
1 gram of tissue. Tissue samples were placed into prechilled 7 mL autoclaved tubes with
prefilled ceramic beads (KT03961-1-302.7, Bertin Instruments, Rockville, MD) and 4 ml of
prechilled PBS supplemented with PenStrep (1:100 w/v). Tissues were homogenized at 8000rpm
for 20 seconds for 4 cycles (Precellys® Evolution Homogenizer, Bertin Instruments, Rockville,
MD). Sample heating was prevented by incubating the tubes on ice between homogenization
cycles. Samples were centrifuged at 15871g (Eppendorf ® 5424, Eppendorf North America,
Hauppauge, NY) for 5 minutes to pellet debris and the supernatant aliquots stored at -80°C until
RNA extraction and quantitative reverse transcription polymerase chain reaction (RT-qPCR)
could be performed.
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Viral RNA extraction
The supernatant from homogenized tissue and the transport media containing the nasal swabs
were used for RNA extraction. Viral RNA was extracted using the MagMAX Pathogen
RNA/DNA Kit (# 4462359) with KingFisher™ Flex Purification System (Thermo Fisher
Scientific, Waltham, MA, USA) following the manufacturer’s high-throughput purification
protocol. Extracted RNA was stored at -80°C until qRT-PCR could be performed.
Virus quantification in nasal swabs and tissue
To quantify viral copy number in nasal swabs and tissue supernatants, RT-qPCR was performed
using standard protocols, primers, and probe validated by the CDC for FLUAV 315 and in-house
designed primers and probe to detect FLUDV (below). Briefly, qRT-PCR was performed in
triplicate by using TaqMan Fast Virus 1-step Master Mix (Life Technology, Carlsbad, CA)
following the manufacturer’s protocol and using 2 µl of RNA template. Samples were amplified
using FLUAV CDC primer and probe set InfA: Forward 5’GACCRATCCTGTCACCTCTGAC-3’; Reverse 5’-AGGGCATTYTGGACAAA CGTCTA-3’;
and Probe 5’-[FAM]-TGCAGTCCTCGCTCA CTGGGCACG-[BHQ]-3’. To detect FLUDV
primer and probe set Forward 5’-ACGCAATGGCACAAGAAC-3’; Reverse 5’ACCACTATGCTCTCTCCAC-3’; and Probe 5’-[FAM]AGGAGTTAACCCAATGACCAGGCAAACGA-[BHQ]-3’ was used. The fast mode
amplification protocol was followed: reverse transcription (1 cycle at 50°C for 5 min),
inactivation (1 cycle at 95°C for 20 sec), followed by 40 alternating cycles of denaturation at
95°C for 3 sec and annealing and extension at 60°C for 1 min.
Viral copies in samples were determined with the standard curve generated by the
plasmid containing the target gene segment (FLUAV M plasmid or FLUDV M plasmid) cloned
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into a dual-promoter plasmid vector, pHW2000, as previously described 268,269. The FLUDV M
plasmid was generously provided by Dr. Richard Webby (St. Jude Children’s Research Hospital,
Memphis, TN). The standard curves were plotted by Ct values against viral copy number/ul
(nasal swabs) or viral copy number/g (tissue homogenate). Average sample Ct values of three
replicates were recorded, and viral copy number concentrations were calculated based on the
standard curve constructed across a series of known target concentrations of plasmid. The data
were presented in figures as log 10 (viral copy number concentration) form.
Histopathological examination
The pigs were euthanized at 5dpi and necropsy was performed to assess macroscopic lesions.
Respiratory tract tissues were fixed in 10% buffered formalin and paraffin embedded and 5 µm
sections were cut and stained with hematoxylin and eosin (H&E) for histopathological
examination.
Caspase stain and quantification
Trachea sections approximately 5 µm were cut from formalin fixed and paraffin embedded
tissues collected at 5dpi during necropsy. Slides were stained with anti-cleaved caspase-3
(Asp175) antibody (Cell Signaling Technology, Catalog #9661) at a 1:200 dilution following the
manufacturer’s protocol for IHC paraffin-embedded tissues. At 200X magnification, the slides
were scanned for the area of most intense staining before adjusting to 400X magnification and
counting all positively stained cells in 20 consecutive high-power fields. The average number of
CC3 positive staining cells from the upper, middle and distal trachea.
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Immunohistochemistry (IHC)
Immunohistochemical staining of respiratory tract tissue was carried out for detection of FLUAV
nucleoprotein. Sections approximately 5µm were cut from formalin fixed paraffin embedded
tissues collected during necropsy (5dpi) including nasal turbinate, trachea and lungs. Slides were
incubated overnight at 65°C, deparaffinized in graded xylenes and rehydrated in graded ethanols
and rinsed in distilled water. Antigen retrieval was performed by placing slides in citrate buffer
at pH 6.0-6.3 (Dako, Catalog #: S202230-2) in a preheated electric steamer for 20 minutes. The
slides were rinsed in distilled water and washed in PBS buffer supplemented with 0.5% Tween.
Endogenous peroxidase activity was quenched with 3% H2O2 for 10 minutes followed by rinsing
and washing in PBS-Tween. Blocking was performed using 10% normal goat serum (Sigma
Catalog #: G9023) for one hour at room-temperature. For FLUAV detection, a 1:500 dilution of
monoclonal anti-FLUAV nucleoprotein (NP) (BEI Resources, NR-43899 Mouse Monoclonal
Anti-Influenza A Virus Nucleoprotein (NP), Clone IC5-1B7, Lot 63323705) was applied and
incubated overnight at 4°C in a humidified chamber. Following primary antibody incubation, the
slides were washed in PBS-Tween and incubated in a 1:500 dilution of biotinylated goat antimouse IgG (Vector Labs, BA-9200) for 30 minutes at room-temperature. Slides were washed in
PBS-Tween and signal detection was enhanced using an avidin/biotin detection system
(VECTASTAIN® ABC HRP Kit) following the manufacturer’s protocol, followed by
incubation in DAB (Vector Labs, SK-4100) for 3 minutes. Slides were counterstained in Mayer’s
hematoxylin for 3 minutes followed by ammonia, dehydrated in ethanol and processed in xylene
prior to coverslipping. No-primary-antibody control was also included.
For FLUDV detection the protocol above was followed except the primary antibody was
an in-house generated polyclonal ferret antisera collected after infection with D/46 as previously
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described 212 followed by the secondary antibody goat anti-ferret IgG (Novus NBP1-73395). No
signal could be detected with the primary antibody at 1:50, 1:25 or no dilution. Additional
experiments were performed to generate positive control slides for testing the FLUDV IHC
detection protocol. MDCK cells were seeded into (4) size 75 flasks and the following day, when
approximately 90% confluent, infected with either FLUAV or FLUDV virus by incubating the
cells in a 1:100 dilution of virus for one hour at 37°C, followed by washing and adding fresh cell
culture media. Approximately 24 hours later the supernatant was confirmed positive for virus by
HA assay using 0.5% turkey red blood cells. Approximately 3mL of trypsin was applied to the
flask and incubated at 37°C until the cells detached. The cells were pelleted and fixed in 10%
buffered formalin for ~72 hours and paraffin embedded. Sections approximately 5 µm were cut
and IHC was performed following the same protocol as IHC for both FLUAV and FLUDV.
FLUDV could not be detected using the primary antibody at 1:50, 1:25 or no dilution. A new
aliquot of primary antibody against FLUDV was tested without any dilution of the primary
antibody; however, no antigen was detected. FLUAV was detected using the protocol above.
Statistical analyses
Differences in CBC data (WBC, segmented neutrophils, lymphocytes and monocytes)
and viral copy number (nasal swabs and tissue homogenates) were analyzed with general linear
mixed models using SAS 9.4 (SAS Institute Inc., Cary, NC). For the CBC data, a repeated
measures analysis (PROC Mixed) included the fixed effects of treatment group, time point (dpi)
and a treatment group x dpi interaction. A repeated statement for pigs measured over dpi was
used with a covariance structure of compound symmetry. Multiple comparison testing was done
with the Tukey-Kramer method. If the treatment group x dpi interaction was not significant, the
interaction term was dropped from the model and the model refit. Findings were considered
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significant when P<0.05. Conditional residual plots were assessed to ensure the assumptions of
normality and homoskedasticity had been met for the models.
For nasal swab data the model was generated with the PROC MIXED procedure in SAS
9.4 (SAS Institute Inc., Cary, NC). The log10 viral copy number was the outcome and included
the fixed effects of treatment group, dpi and a treatment group x dpi interaction. A repeated
statement with pigs as the subject measured over dpi was used with an autoregressive covariance
structure. For tissue data the model included the fixed effects of treatment group, tissue
(turbinate, trachea, soft palate and lower respiratory tract), and the treatment group x tissue
interaction and a random effect of pig that used a variance components covariance structure. For
significant terms in the nasal swab and tissue models, the simulate option for adjustment for
multiple comparisons of least squares means was used. Diagnostics of the models included visual
analysis of the Q-Q plot that showed the residuals were approximately normally distributed and
the residual vs predicted plot that showed the model met the assumption of homoscedasticity of
error variance. Differences were considered significant at P < 0.05.
The CC3 data were log10-transformed and subjected to the Shapiro–Wilk's test of
normality and Brown-Forsythe test for homogeneity of variance. A One-way ANOVA followed
by Tukey’s multiple-comparisons test was performed. Differences were considered significant at
P < 0.05. Analysis was performed in GraphPad Prism version 8.2.1 for Windows (GraphPad
Software, San Diego, CA).
Results
Clinical Data
The piglets were farrowed by sows vaccinated against influenza at 84 days gestation and
were expected to have maternal antibodies to diverse FLUAV subtypes (Figure 4.1). HI assay
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was used to measure the serological response of waning maternal antibodies to FLUAV. The
majority of the pigs had no detectable HI titer to any testing viruses after 11 weeks but because
some pigs still had a detectable HI titer, the testing continued periodically until the pigs were
approximately 16 weeks old, including the day of the infection challenge where the serum was
stored at -20°C until the end of the study. A small group of pigs still had detectable HI titer to
FLUAV and because they did not meet the criteria for infection challenge they were excluded
from data analysis after being inoculated according to their assigned treatment group.
Approximately 16 week old pigs were intranasally inoculated with FLUDV (n=7), FLUAV
(n=5), FLUADV + FLUAV (n=7) or sterile PBS (n=6) and monitored daily for 5dpi. To assess
clinical signs of influenza infection, prior to entering the enclosure, pigs were observed from a
window for changes in attitude, elevated respiratory rate, cough, dyspnea, nasal or ocular
discharge or conjunctivitis. No obvious signs of respiratory infection were observed. In the
FLUDV group, pig 55 stood quietly and remained separate from the others at 1 and 2dpi and the
same quiet behavior was observed for pig 63 at 1, 2 and 3dpi. Pig 55 had a detectable HI titer to
FLUAV immediately prior to the infection challenge and was excluded from data analysis but
pig 63 did not. In the FLUAV group, pig 51 also stood quietly and remained separate from the
others at 1 dpi. Clinical observation data suggests the pigs were asymptomatic for influenza
infection.
To assess for fever, pig rectal temperatures were obtained daily. Normal rectal
temperatures for pigs are in the range of 101.5-102.5°F though heat, humidity and stress will
increase the upper range. Rectal temperatures for most pigs were generally elevated for all time
points during the study (Figure 4.2). The mean temperature + standard error of the mean (SEM)
for each group included: Control (103.1°F + 0.1 SEM); FLUDV (103.5°F+ 0.1 SEM); FLUAV
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(103.1°F+ 0.2 SEM); and Coinfection (103.3°F+ 0.3 SEM). The elevated baseline temperatures
observed prior to and throughout the study was likely due to factors such as excitement and
stress during handling and restraint, including snaring as the animals were housed in temperature
controlled facilities.
Whole blood was collected from each pig at 0, 3 and 5 dpi and processed by MSU-CVM
Diagnostic Lab within 24 hours. A CBC for each pig was obtained and included mean leukocyte
(WBC) count, segmented neutrophils, lymphocytes and monocytes (Figures 4.3 – 4.6). The CBC
data are unremarkable and in the context of asymptomatic animals, less biologically relevant;
however least squares mean segmented neutrophils in the FLUAV treatment group (9102 K/µl +
581 SEM) were higher than in the coinfection group (6722 K/µl + 549 SEM) (P=0.024).
Although there was no reference interval for pigs available from the lab performing the test; a
standard hematologic reference range for segmented neutrophil counts in pigs is 2-15 K/µl 316
and all treatment pigs were within this range. There were no differences in the mean WBC,
lymphocyte or monocyte counts between treatment groups (P>0.153) or at any time point
(P>0.062).
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Figure 4.1

Serological response against selected FLUAVs by HI assay

Piglets were farrowed from sows vaccinated against FLUAV at 84 days gestation and circulating
maternal antibodies to FLUAV were suspected. HI assay was repeated at regular intervals to
monitor declining maternal antibodies. Only pigs without detectable antibodies to diverse
influenza strains, including the challenge viruses Texas/A01104013/2012 and FLUDV (D/46,
not shown), were included in the study. The treatment pigs were approximately 16 weeks old at
the time of the infection study.
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Figure 4.2

Mean rectal temperature of pigs

Pig rectal temperatures were taken daily. Each data point includes the mean temperature for the
treatment group and error bars represent the standard error of the mean (SEM). Normal rectal
temperatures for pigs are in the range of 101.5-102.5°F. The mean temperature + SEM for each
group included: Control (103.1°F + 0.1); FLUDV (103.5°F+ 0.1); FLUAV (103.1°F+ 0.2); and
Coinfection (103.3°F+ 0.3). High baseline temperatures were observed prior to and throughout
the study, likely due to factors such as excitement and stress during handling and restraint.
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Figure 4.3

Total white blood cell (WBC) count in pigs

Whole blood was collected from each pig at 0, 3 and 5 dpi and stored at 4°C until processing
within 24 hours by MSU-CVM Diagnostic Lab. Each data point includes treatment group mean
WBC count and error bars represent the standard error of the mean.
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Figure 4.4

Segmented neutrophils in pigs

Whole blood was collected at 0, 3 and 5 dpi and stored at 4°C until processing within 24 hours
by MSU-CVM Diagnostic Lab. Each data point includes the mean segmented neutrophil count
for the treatment group and error bars represent the standard error of the mean. The segmented
neutrophil counts in the FLUAV treatment group were higher than the COINF group (P=<0.05)
but both groups were within the standard hematologic reference range of 2-15 K/µl.
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Figure 4.5

Lymphocyte counts in pigs

Whole blood was collected at 0, 3 and 5 dpi and stored at 4°C until processing within 24 hours
by MSU-CVM Diagnostic Lab. Each data point includes the mean lymphocyte count for the
treatment group and error bars represent the standard error of the mean. There was no difference
in lymphocyte counts between groups or time points.
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Figure 4.6

Monocyte count in pigs

Whole blood was collected at 0, 3 and 5 dpi and stored at 4°C until processing within 24 hours
by MSU-CVM Diagnostic Lab. Each data point includes the mean monocyte count for the
treatment group and error bars represent the standard error of the mean. There was no difference
in monocyte counts between groups or time points.
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Viral Quantification
Nasal Shedding
Viral copy numbers in nasal swabs taken daily from 0-5dpi were quantified using RTqPCR (Figure 4.7; Tables 4.2-3). The limit of detection of the assay was 3.477 log10copies/mL.
Nasal shedding results showed that in single infections, 5/5 pigs shed FLUAV and 6/7 pigs shed
FLUDV at 3, 4 and/or 5 dpi, respectively. In the COINF group 7/7 pigs shed FLUAV but only
1/7 pigs shed FLUDV at 3, 4 and/or 5 dpi. Although dpi had a significant effect on FLUAV viral
copy number (P<0.001), neither the treatment group (P=0.152) or treatment group x dpi
interaction (P=0.6157) was significant. Least squares means FLUAV viral copy number on 2dpi
(3.910 log10 copies/mL) were lower than dpi3 (5.716, P<0.001) and dpi5 (4.989 log10
copies/mL, P=0.010) but not on dpi4 (4.610 log10 copies/mL, P=0.133). FLUAV viral copy
number on dpi3 was greater than on dpi4 (P=0.005), but not on dpi5 (P=0.112). No difference
was detected between FLUAV viral copy numbers on dpi4 and dpi5 (P=0.587).
The least squares means FLUDV copy number for the single infection group (4.214
log10 copies/mL) was greater (P<0.001) than for the coinfection group (3.508 log10 copies/mL).
Dpi had a significant effect on FLUDV viral copy number (P=0.050) in the model but no
differences between dpi were detected following adjustment for multiple comparisons. A
significant treatment group x dpi interaction effect on FLUDV viral copy number was not
detected (P=0.080).
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Table 4.2

a
b

FLUDV viral copy number (log10copies/ml) in nasal swabs
Pig

Group

1a

2

3

4

5

53
58
60
66
79
82
54
61
63
64
70
71
74
52
57
67
68
72
73
81

Control
Control
Control
Control
Control
Control
FLUDV
FLUDV
FLUDV
FLUDV
FLUDV
FLUDV
FLUDV
COINF
COINF
COINF
COINF
COINF
COINF
COINF

ND b
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
4.202
ND
4.516
ND
3.833
6.659
3.876
3.545
ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
4.191
4.726
5.022
ND
5.588
ND
4.094
3.953
ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
6.283
4.570
4.827
ND
5.871
4.528
ND
3.802
ND
ND
ND
ND
ND
ND

days post inoculation
not detected with a limit of detection of 3.477 log10copies/mL
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Table 4.3

a
b

FLUAV viral copy number (log10copies/ml) in nasal swabs
Pig

Group

1a

2

3

4

5

53
58
60
66
79
82
51
56
62
69
75
52
57
67
68
72
73
81

Control
Control
Control
Control
Control
Control
FLUAV
FLUAV
FLUAV
FLUAV
FLUAV
COINF
COINF
COINF
COINF
COINF
COINF
COINF

ND b
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
ND
4.065
4.485
4.993
ND
ND
ND
ND
ND
ND
ND
5.184

ND
ND
ND
ND
ND
ND
7.662
5.864
6.574
4.832
5.591
ND
4.636
5.926
6.180
5.056
5.835
6.183

ND
ND
ND
ND
ND
ND
5.014
5.456
4.189
4.823
4.231
4.446
ND
5.256
4.834
ND
4.813
5.033

ND
ND
ND
ND
ND
ND
5.237
4.535
4.950
4.290
5.803
4.585
5.655
6.012
4.719
4.860
4.599
4.672

days post inoculation
not detected with a limit of detection of 3.477 log10copies/mL
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Figure 4.7

Viral quantification of nasal swabs by RT-qPCR

Viral replication was quantified with qRT-PCR. Each data point includes the mean per treatment
group and error bars represent SEM. The dashed line indicates the limit of detection of 3.477
log10copies/mL. A/B) FLUAV shedding was not different in the single vs coinfection groups (P>
0.05); C/D) the least squares means FLUDV copy number for the single infection group (4.214
log10 copies/mL) was greater (P<0.001) than for the coinfection group (3.508 log10 copies/mL).
No virus was detected in the control group (not shown).
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Tissue Viral Load
We used RT-qPCR to quantify viral copy number in respiratory tract tissues collected at
necropsy on 5dpi (Figure 4.8; Tables 4.4-5). The 14 respiratory tract tissues were categorized
into four groups: turbinate (rostral, middle, ethmoid turbinate), trachea (upper, middle, distal),
soft palate, and lower respiratory tract (bronchus, lung lobes from left cranial and caudal, and
right cranial, caudal, middle and accessory). In the single and coinfection groups, all pigs were
positive for FLUAV with a limit of detection of 4.028 log10copies/g (Table 4.4). There was no
difference in FLUAV replication in the single infection compared to the coinfection group
(P=0.916) or due to the treatment group x tissue interaction (P=0.301). There was a significant
tissue effect on FLUAV viral copy numbers (P<0.001). Least squares means FLUAV viral copy
numbers for turbinate (8.198 log10 copies/g) were greater than lower respiratory tract (7.248
log10 copies/g, P<0.001), soft palate (7.491 log10 copies/g, P=0.009), and trachea (7.301 log10
copies/g, P<0.001).
All pigs in the single and coinfection groups were RT-qPCR positive for FLUDV with a
limit of detection of 4.028 log10copies/g (Table 4.5). FLUDV replication was higher in the
turbinate and soft palate in the single infection than the coinfection group. Specifically, there
were differences between the turbinate with 6.71 vs 4.88 log10copies/g (P=0.002) and the soft
palate with 6.23 vs 4.45 log10copies/g (P=0.003) for single infection FLUDV and coinfection,
respectively. The trachea and lower respiratory tract showed no difference in FLUDV viral copy
number when comparing single and coinfection groups (P=0.965). FLUDV replication was
lowest in the lower respiratory tract at 4.46 and 4.25 log10copies/g, for single and coinfection
groups, respectively. In the single infection FLUDV group, FLUDV replication was greatest in
the turbinate at 6.71 log10copies/g and less in the trachea at 4.84 log10copies/g (P<0.001) and
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lower respiratory tract at 4.46 log10copies/g (P<0.001). Differences were also significant between
the soft palate at 6.23 log10copies/g and lower respiratory tract at 4.46 log10copies/g (P<0.001)
and trachea at 4.84 log10copies/g (P=0.001). In the coinfection group, FLUDV replication was
higher in the trachea at 5.27 log10copies/g than in the lower respiratory tract at 4.25 log10copies/g
(P=0.032). There were no other differences between tissues in the coinfection group (P>0.137).
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Table 4.4
Pig

a

FLUAV viral copy number (log10copies/g) in respiratory tract tissues

RT

MT

ET

SP

TRU

Respiratory Tissue a
TRTRM
D
BR
LCR

Group

LCD

RCR

RCD

RM

RA

53

Control

ND b

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

58

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

60

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

66

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

79

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

82

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

51

FLUAV

9.43

9.22

5.27

8.35

7.11

7.45

7.06

6.26

6.88

9.26

7.43

6.99

7.44

8.15

56

FLUAV

8.75

9.60

7.01

7.34

5.12

5.87

5.92

7.74

6.16

6.16

7.97

7.05

7.66

6.94

62

FLUAV

9.34

9.90

6.46

7.55

7.43

7.73

7.55

7.52

7.99

7.74

6.35

7.46

8.09

7.56

69

FLUAV

8.08

8.21

7.19

7.58

7.27

7.76

7.75

7.06

8.37

8.47

7.65

8.25

5.99

7.51

75

FLUAV

7.35

9.19

7.50

7.13

6.86

8.21

7.30

7.55

7.29

7.62

5.29

7.64

6.99

7.19

52

COINF

7.62

9.65

7.46

7.48

6.17

7.49

7.71

7.62

7.25

6.65

8.22

7.51

7.07

5.54

57

COINF

8.50

9.36

7.01

7.47

8.61

8.38

8.49

7.20

7.89

8.02

5.86

7.29

7.36

6.76

67

COINF

8.58

9.70

7.31

7.97

7.45

7.06

7.40

8.57

6.82

8.38

7.68

7.63

7.09

5.73

68

COINF

8.81

9.63

7.57

7.41

7.17

6.78

7.77

7.15

6.69

6.59

7.00

6.96

5.77

5.35

72

COINF

7.76

8.89

6.96

7.19

7.49

6.71

7.42

7.84

6.94

7.08

6.88

7.03

7.20

7.46

73

COINF

7.75

8.00

6.69

6.92

7.81

8.09

8.31

6.92

6.44

7.79

7.36

8.26

7.35

6.90

81

COINF

8.89

9.52

7.16

7.32

7.66

6.99

6.76

7.69

7.75

6.74

6.26

6.64

7.50

7.88

Abbreviations: rostral turbinate (RT), middle turbinate (MT), ethmoid turbinate (ET), soft
palate (SP), upper trachea (TR-U), middle trachea (TR-M), distal trachea (TR-D), bronchus
(BR), left cranial lung (LCR), left caudal lung (LCD), right cranial lung (RCR), right caudal lung
(RCD), right middle lung (RM) and right accessory lung (RA)
b
Not detected with a limit of detection of 4.028 log10copies/g
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Table 4.5
Pig

a

FLUDV viral copy number (log10copies/g) in respiratory tract tissues

RT

MT

ET

SP

TRU

Respiratory Tissue a
TRTRM
D
BR
LCR

Group

LCD

RCR

RCD

RM

RA

53

Control

ND b

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

58

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

60

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

66

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

79

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

82

Control

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

54

FLUDV

7.01

7.12

5.52

6.40

ND

ND

4.08

4.06

4.99

ND

4.55

ND

5.01

ND

61

FLUDV

NA c

NA

5.10

5.17

4.74

4.38

4.46

ND

4.13

ND

4.19

4.09

ND

4.14

63

FLUDV

7.11

8.79

5.57

7.06

4.93

5.55

5.40

ND

ND

4.18

ND

ND

ND

ND

64

FLUDV

6.06

6.62

4.91

6.56

4.05

ND

4.36

ND

4.86

ND

ND

ND

ND

ND

70

FLUDV

7.53

8.37

7.83

5.52

6.82

5.58

4.85

ND

4.03

5.24

5.18

4.48

4.46

ND

71

FLUDV

8.66

9.19

5.21

7.16

7.05

4.82

5.00

6.87

6.87

5.68

5.23

5.91

5.48

4.70

74

FLUDV

7.89

7.75

4.56

5.75

4.61

4.28

4.61

4.43

ND

ND

4.19

4.62

4.48

ND

52

COINF

6.47

8.70

5.90

5.10

7.52

7.97

7.26

6.85

4.77

4.37

4.25

4.56

5.24

4.04

57

COINF

ND

5.09

4.96

4.57

4.09

5.35

5.78

4.38

ND

4.93

ND

ND

ND

ND

67

COINF

ND

4.68

ND

ND

6.56

6.68

5.84

ND

ND

ND

5.23

ND

4.83

4.15

68

COINF

ND

5.01

ND

4.80

4.21

ND

5.22

ND

4.94

ND

ND

ND

ND

ND

72

COINF

4.43

5.82

4.88

4.57

4.49

4.83

ND

ND

ND

ND

ND

ND

ND

ND

73

COINF

4.55

ND

ND

ND

5.01

4.13

4.22

ND

ND

4.56

ND

ND

ND

ND

81

COINF

4.62

5.22

ND

ND

ND

4.76

4.58

ND

ND

ND

4.12

ND

ND

ND

Abbreviations: rostral turbinate (RT), middle turbinate (MT), ethmoid turbinate (ET), soft
palate (SP), upper trachea (TR-U), middle trachea (TR-M), distal trachea (TR-D), bronchus
(BR), left cranial lung (LCR), left caudal lung (LCD), right cranial lung (RCR), right caudal lung
(RCD), right middle lung (RM) and right accessory lung (RA)
b
Not detected with a limit of detection of 4.028 log10copies/g
c
Not available
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Figure 4.8

Viral copy number in respiratory tract tissues

Viral replication was quantified with qRT-PCR. Each data point includes the mean per treatment
group and error bars represent SEM. The dashed line indicates the limit of detection of the assay
of 4.028 log10copies/g. A/B: There was no difference in FLUAV replication in the single
infection group compared to the coinfection group (P=0.916). C/D: FLUDV replication was
higher in the single infection group than coinfection group in the turbinate with 6.71 vs 4.88
log10copies/g (P=0.002) and the soft palate with 6.23 vs 4.45 log10copies/g (P=0.003).
Abbreviations: rostral turbinate (RT), middle turbinate (MT), ethmoid turbinate (ET), soft palate
(SP), upper trachea (TR-U), middle trachea (TR-M), distal trachea (TR-D), bronchus (BR), left
cranial lung (LCR), left caudal lung (LCD), right cranial lung (RCR), right caudal lung (RCD),
right middle lung (RM) and right accessory lung (RA). No virus was detected in the control
group (not shown).
Immunohistochemistry and Histopathology
The pigs were euthanized at 5dpi and respiratory tract tissues were fixed in 10% buffered
formalin and paraffin embedded and 5 µm sections of trachea H&E stained for histopathological
examination by a boarded pathologist who was blinded to treatment groups (Figure 4.9). All
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trachea tissues showed some degree of chronic lymphocytic inflammation within the epithelium
and submucosa that made further histopathologic analysis for acute infection challenging.
Apoptotic bodies and mitotic figures were frequently observed in the coinfection group.
Therefore, the trachea tissues were stained with antibodies against cleaved caspase-3 (CC3)
(Figure 4.10), a downstream effector caspase and an important regulator of apoptosis.
To quantify CC3 positive cells, we performed a manual count from 20 consecutive highpower fields for each trachea section (upper, middle and distal) to obtain the average count per
pig. This value was used to determine the mean number of CC3 positive cells per treatment
group and differences compared in a one-way ANOVA. In the FLUAV group, the mean number
of CC3 positive cells was 93 (+ 22 SEM; range: 47-174) and this was higher than staining
quantified in the control group 19 (+ 3 SEM; range 12-27) (P= <0.05). In the FLUDV group, the
mean number of CC3 positive cells was 96 (+ 41 SEM; range: 15-248). In the FLUDV group,
four pigs had low numbers of CC3 positive cells but the counts were high for pigs 61 and 71
(Figure 4.10). Interestingly, pig 71 was the only pig in the FLUDV group that was RT-qPCR
positive for all respiratory tract tissues sampled (Table 4.4). In the COINF group, the mean was
50 (+12 SEM; range: 19-99).
IHC was performed to localize FLUAV and FLUDV antigen by cell type and severity
within the upper, middle and lower respiratory tract tissues. There was abundant expression of
FLUAV nucleoprotein in the epithelial cells of the upper respiratory tract of FLUAV and COINF
pigs at 5dpi including the turbinate (Figure 4.11 and Figure 4.12) and the trachea (Figures 4.13
and 4.14). In the lower respiratory tract, FLUAV nucleoprotein positive cells were very
infrequently located. A small number of FLUAV nucleoprotein positive cells were present in the
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left cranial lung of pig 57 in the COINF group (Figure 4.12). No-primary-antibody control did
not show any staining.

Figure 4.9

Histopathology of trachea

H&E staining of tracheas from A) Control pig 66; B) FLUDV pig 61; C) FLUAV pig 69; D)
COINF pig 67. All tracheal tissues A-D showed some degree of chronic lymphocytic
inflammation within the epithelium and submucosa. D) Apoptotic bodies (arrows) and mitotic
figures (not shown) within the epithelium were frequently observed in the coinfection group.
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Figure 4.10

Cleaved caspase 3 staining in the trachea

CC3+ cells from the upper, middle and distal trachea were quantified in each pig. At 200X magnification, the slides were
scanned for the area of most intense staining before adjusting to 400X magnification and counting all positively stained cells in
20 consecutive high-power fields. A) CC3+ cells were higher in the FLUAV infected pigs than control pigs. The group mean is
shown and error bars represent the standard error of the mean. B-E: CC3+ cells in the distal trachea of B) control pig 53; C)
FLUAV pig 69; D) FLUDV pig 71; and E) COINF pig 68; Scale bar = 50 µm.
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Figure 4.11

Expression of FLUAV nucleoprotein in turbinate of FLUAV pig

There was abundant expression of FLUAV nucleoprotein (brown) in the epithelial cells of the
upper respiratory tract of FLUAV pigs at 5dpi. Shown above is turbinate from pig 62. Scale bar
is 20 µm.
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Figure 4.12

Expression of FLUAV nucleoprotein in turbinate of COINF pig

There was abundant expression of FLUAV nucleoprotein (brown) in the epithelial cells of the
upper respiratory tract of COINF pigs at 5dpi. Shown above is turbinate from pig 52. Scale bar is
20 µm.
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Figure 4.13

Expression of FLUAV nucleoprotein in trachea of FLUAV pig

There was abundant expression of FLUAV nucleoprotein (brown) in the epithelial cells of the
upper respiratory tract of FLUAV pigs at 5dpi. Shown above is trachea from pig 69. Scale bar is
20 µm.
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Figure 4.14

Expression of FLUAV nucleoprotein in trachea of COINF pig

There was abundant expression of FLUAV nucleoprotein (brown) in the epithelial cells of the
upper respiratory tract of COINF pigs at 5dpi. Shown above is trachea from pig 67. Scale bar is
20 µm.
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Figure 4.15

Expression of FLUAV nucleoprotein in the lower respiratory tract

There was minimal expression of FLUAV nucleoprotein (brown) in the lower respiratory tract at
5dpi of either the FLUAV or COINF groups. A small number of positive cells were present in
the left cranial lung of pig 57 in the COINF group. Scale bars indicate 20 µm.
Discussion
The objective of our study was to characterize the pathogenicity of FLUAV + FLUDV
same exposure coinfection in domestic pigs. Our data showed no difference in FLUAV nasal
shedding, viral replication or tissue tropism between single and coinfected pigs, suggesting
simultaneous coinfection is permissive for FLUAV replication with minimal alterations in
pathogenicity. However, our data showed FLUDV nasal shedding and viral replication in
turbinate and soft palate was decreased in the coinfected pigs suggesting coinfection may have
antagonistic effects on FLUDV viral replication. However, a limitation of our study was the
logistical necessity of sacrificing all animals at one timepoint (5dpi), therefore our findings are
not necessarily applicable to earlier in the time course of infection.
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Our pigs were asymptomatic for respiratory tract infection. Under experimental
conditions, typical disease is unlikely after intranasal inoculation of most influenza strains in pigs
and can only be induced by intratracheal inoculation of a high virus dose (≥7.0 log10ID50) leading
to enhanced replication in the lungs and activation of a rapid and overwhelming immune
response 314. However, intranasal inoculation simulates a more natural route of infection 314 and
our goal was to reflect the natural ecology and epidemiology of influenza exposure in pigs. The
pigs in our study had elevated body temperatures, but these findings were attributed to the
increased physical activity and stress associated with handling and restraint, including the
necessity of snaring. In previous FLUAV or FLUDV studies, pigs were also subclinical or had
mild clinical signs 25,226,287,317. Other clinical data, i.e. CBC, was not a helpful marker of
pathogenicity, and this was consistent with another FLUDV study in cows 212 and FLUAV study
in pigs 317. In human studies, an early lymphopenia has been proposed as a helpful screening tool
for further influenza diagnostics in resource limited situations 318,319. Lymphopenia has also been
observed as early as 3dpi in FLUAV experimentally infected pigs, however, this may be strain
and dose dependent and correlation to pathogenicity is unclear 320. Although clinical signs
weren’t apparent, detection of viral shedding in nasal swabs, virus quantification in respiratory
tract tissues and/or antigen detection using IHC indicates successful infection.
Immunohistochemistry and virus quantification in the upper respiratory tract and trachea
show that pigs in single and coinfection groups were comparably infected by FLUAV. FLUAV
detection was widespread in epithelial cells in the turbinate and trachea of single and coinfected
groups and viral replication data supported this conclusion. Although virus quantification
showed FLUAV replication in the lower respiratory tract, detection of FLUAV nucleoprotein by
IHC was very limited in this region for both single and coinfected groups. Virus quantification of
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FLUDV suggested replication was more robust in the upper respiratory tract of the single
infection group and reduced in the coinfection group. In the lower respiratory tract, FLUDV
replication was comparably poor in both the single and coinfection groups. Being unable to
detect FLUDV by IHC was another limitation of the study because we were unable to determine
if the virus was as widespread as FLUAV.
Histopathological assessment for acute infection was challenging in the presence of
widespread chronic lymphocytic inflammation. Previous studies in our lab relied upon the use of
widely available feral swine but this model proved challenging due to the unknown health status,
pathogen exposure and parasite burden of feral swine. By utilizing domestic swine farrowed at
the university, we hoped to avoid this limitation but unfortunately, the herd still showed signs of
chronic respiratory inflammation. This was likely attributed to weather exposure, i.e. abrupt
cycles of wet, cold and warm Spring weather, as we waited for the pigs to test seronegative.
Ideally, we would have had access to piglets from unvaccinated sows and conducted our
experiment earlier. Immunohistochemistry against CC3+ cells, a marker of apoptosis, showed
apoptosis higher in the FLUAV group. FLUAV has been shown to induce apoptosis in vitro in
numerous cell types including monocytes 321, lymphocytes 318,322 and human airway epithelial
cells 323 and in vivo in mice 324; however, the molecular mechanisms and outcomes are not well
understood and are likely dependent on cell type, viral strain and host 325. Three different
subtypes of SIV-FLUAV (H1N1, H3N2, and H1N2) have been shown to induce apoptosis in
porcine kidney cells, swine testicle cells, and HeLa cervical carcinoma cells 326.
In the literature there is limited data regarding pathogenicity of single infection FLUDV
in any host species. FLUDV tropism for the upper and/or lower respiratory tract has been
somewhat inconsistently reported although some variation can be attributed to differences in
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strain, dose, inoculation route, animal host and study endpoint. Under laboratory conditions,
FLUDV has been shown to replicate in the upper and lower respiratory tracts of guinea pigs
infected with a bovine strain of FLUDV 327. In our current study, single infection with FLUDV
showed poor replication in the lower respiratory tract of pigs at 5dpi. In the previous study of
domestic swine, lung samples collected 7dpi were not FLUDV positive by RT-qPCR and
histopathological examination of the lungs revealed no evidence of typical influenza lesions 25.
In our previous study of FLUDV in feral swine, replication was also lowest in the lungs at 5dpi
226

. Our data generally agree with the previous study in domestic pigs that first detected FLUDV

in nasal shedding at 3dpi 49. However, our present study ended at 5dpi whereas the previous
study was longer and showed that shedding peaked at 8dpi 49. Our previous study of feral swine
also detected FLUDV in nasal swabs at 3dpi with a peak titer at 5dpi 226. As others have noted,
the replication kinetics for FLUDV appear slower than FLUAV in domestic swine and ferrets 49.
Replication kinetics of the two viruses may be an important element of competitive fitness in
simultaneous exposure coinfection.
Respiratory disease complex is a multifactorial disease in cattle, pigs, dogs, humans and
other hosts but research frequently focuses on viral-bacterial coinfections that are often
synergistic and considerably less is known about viral-viral coinfections. Bacterial coinfection
was identified as a critical factor in the mortality of the 1918 FLUAV pandemic 235,236. Swine
influenza viruses recognize the α2,6 sialic acids in the capsule of Streptococcus suis and both
pathogens are significant contributors to porcine respiratory disease complex 233. While viralbacterial relationships are frequently synergistic, VVIs between influenza and other respiratory
viruses are mostly competitive or neutral including VVIs with respiratory syncytial virus,
rhinovirus, human parainfluenza virus and other influenza viruses 232. Data shows VVIs between
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Newcastle Disease virus (NDV)-LPAI and NDV-HPAI in poultry are generally antagonistic
238,328

. A mouse model of coinfection with unrelated respiratory viruses, mildly pathogenic

rhinovirus RV1B and virulent mouse-adapted PR8 influenza, suggested there was interference
240

. When the mild pathogen was administered 48 hours prior, there was reduced disease severity

at low and medium, but not high doses, of influenza. PR8 replication was not reduced but
clearance was enhanced. Substituting RV1B for mouse hepatitis virus strain 1 (MHV-1),
suggested the exclusion was not virus specific, although MHV-1 infection was associated with
reduced PR8 replication and upregulation of beta interferon.
Superinfection exclusion (SIE) is a specific type interference that occurs when a
preexisting viral infection prevents a secondary infection with the same or a closely related virus
246

. Relatively few studies have examined coinfection outcomes with influenza from different

genera, i.e. unable to undergo reassortment. In 1944, Ziegler and Horsfall demonstrated SIE
between A/PR 8/34 (H1N1), Shope’s 1976 swine influenza 249 and the Lee strain of FLUBV 250
and also identified key temporal and dose-dependent outcomes. Contemporary studies also
demonstrate influenza SIE. A study of A549 human epithelial cells infected with H1N1 and
H3N2 suggested that the NA protein limits superinfection for 6 hours post-primary infection 251.
Another study also showed a six hour delay (sequential exposure coinfection) produced robust
SIE, whereas simultaneous inoculation resulted in coinfected cells approaching 100% 252. Similar
results were obtained using Vero cells that lack type I interferon secretion, suggesting SIE does
not depend on IFN secretion 252 . Their data also suggested that although NA enzymatic activity
correlated with higher SIE, it wasn’t dependent upon NA activity but rather by the number of
viral genes and MOI 252.
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Temporal aspects of SIE have also been demonstrated in vivo, in single cell studies and in
heterosubtypic and antigenically unrelated influenza viruses. An in vitro study in MDCK cells
and an in vivo guinea pig model compared reassortment efficiency in synchronous and sequential
coinfections in the absence of segment mismatch using seasonal H3N2 variants, rPAN/99wt and
rPan/99var 253. High MOI synchronous infection led to an 88.4% reassortant rate but this
decreased to 47.5% at an eight hour infection interval and only 4.75% at a 12 hour interval 253. In
the guinea pig model, there was moderate reassortment at 0 and 6 hour intervals, robust
reassortment at 12 hours, minimal reassortment at 18 hours and no reassortment at 24, 48 or 72
hour intervals 253. Another recent study used a viral RNA labeling design to quantify coinfection
of FLUAV WSN/33 (H1N1) in MDCK cells and showed the secondary virus had to coinfect
cells within two to three hours of the primary virus to be successful and after this timepoint the
secondary virus was restricted for the duration of the infection 254. The secondary virus was still
capable of entering the cell but could not shift to replication, suggesting replication of the
primary virus impaired nuclear import of the gene segments 254. A ferret animal model compared
coinfection of antigenically unrelated FLUAV vs FLUBV and heterosubtypic FLUAV (H1 and
H3) with the secondary challenge occurring 1,3,5,7, 10, and 14 days post primary challenge 239.
Viral interference depended upon the time interval between infections and the sequential
combination of viruses. When FLUAV pH1N1 was administered one or three days prior to
FLUBV, half of the ferrets did not shed FLUBV but if FLUBV was the primary challenge, the
ferrets became coinfected and shed both viruses.
In surveillance studies in humans, respiratory tract coinfection seems common but
exposure to heterosubtypic and antigenically unrelated influenza viruses appears rare. In one
study of human patients with influenza-like illness, an eight panel respiratory virus PCR was
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performed and data showed an overall coinfection rate of 41% (10,501/25,596) with 7.3%
(57/779) coinfected with seasonal FLUAV and another respiratory virus and only 2% (16/779)
were coinfected with seasonal FLUAV and FLUBV 242. In the same study, 4.7% (137/2689) of
patients were coinfected with pH1N1 FLUAV and another virus, but none were coinfected with
another influenza. Determining the clinical significance of mixed infections has been even more
challenging than detection. A 2014 meta-analysis of 21 studies (n = 4,280 patients), identified no
significant differences in clinical disease severity between viral coinfections and single
respiratory infections 244. A 2016 meta-analysis of 43 studies (n = 17, 234 patients under the age
of 18) found no significant difference in clinical outcomes between the single and multiple
infections 245. Outcomes assessed included need for hospitalization, length of hospital stay, use
of supplemental oxygen, mechanical ventilation, admission to the intensive care unit and death.
Future directions for our present study will utilize an ex-vivo organ culture (EVOC) model to
investigate pathogenicity of FLUAV, FLUDV and FLUAV+FLUDV replication at more
frequent intervals post inoculation. Lung and trachea explants are both reasonably wellestablished techniques for ex-vivo influenza infection and could be used to account for
differences in tissue tropism. Furthermore, this design could feasibly test a sequential infection
time course in addition to simultaneous infection. Quantifying the primary proinflammatory
cytokines such as tumor necrosis factor (TNF)–α, interleukin (IL)–1, and IL-6 and correlating
those levels to virus replication would offer additional insight into the pathogenicity of these
viruses in pigs. If coinfection led to a higher or more prolonged virus replication, excessive
cytokine induction, and/or replication in the lower respiratory tract, this would presumably lead
to enhanced pathogenicity. Data obtained from these additional studies would address significant
knowledge gaps.
133

CHAPTER V
CONCLUSIONS
Emerging influenza viruses are a persistent threat to animal and public health. The
dissertation characterized the prevalence, pathogenicity and zoonotic risk of emerging influenza
viruses from domestic species. The data in this dissertation have generated the following
conclusions:
The zoonotic risk, pathogenesis and transmission of avian-origin CIV-H3N2 was
characterized by generating reassortant progeny from coinfection of CIV-H3N2 and 2009
pH1N1. Characterizing all 127 possible reassortant viruses as high growth, moderate growth, or
unable to generate aided in the selection of 19 reassortant viruses with potential for enhanced
pathogenicity. The high growth reassortants were characterized in mice and 13 replicated
efficiently in mice lungs. A reassortant with the HA and NP genes derived from CIV-H3N2
transmitted efficiently by direct contact in ferrets and was more pathogenic than wild-type CIVH3N2. Our results suggest that CIV-H3N2 reassortants may pose a moderate risk to public
health and that the canine host should be monitored for emerging FLUAVs. In chapter three, we
addressed the need for influenza surveillance in the canine population by conducting a
seroepidemiological analysis of FLUAV exposure in shelter-owned dogs in Mississippi, a
population not previously investigated. We sampled 565 dogs from eighteen shelters statewide
and identified 7/565 dogs (1.2%) ELISA positive (S/N < 0.70) for FLUAV exposure but no
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positive dogs by HI assay. Our data suggests the shelter dog population may have limited
exposure to FLUAV.
In chapter four, we characterized the pathogenicity and tissue tropism of FLUAV,
FLUDV and FLUDV + FLUAV coinfection in domestic pigs and offer insight as to whether
coinfection increases pathogenesis in swine compared to infection of FLUDV or FLUAV alone.
Our findings suggest simultaneous exposure coinfection does not alter nasal shedding or tissue
viral load of FLUAV but coinfection is associated with reduced nasal shedding and tissue viral
load of FLUDV. Collectively, this dissertation offers insight into emerging influenza viruses
originating in dogs and pigs and potential antagonistic outcome of coinfection with influenza
viruses not originating from the same genus and, by definition, cannot reassort. The latter is an
emerging but neglected area of influenza research.
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ELISA RESULTS OF MISSISSIPPI SHELTER DOG SERA AGAINST FLUAV
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SD indicates standard deviation of three replicates; those highlighted in bold are the samples
determined to be positive using the S/N threshold > 0.70.
Sera ID

S/N (SD)

99
238

0.28 (0.03)
0.58 (0.05)

543

0.6 (0.01)

259

0.7 (0.07)

348

0.7 (0.08)

567

0.7 (0.1)

219

0.7 (0.13)

263

0.72 (0.08)

229

0.75 (0.04)

385

0.75 (0.05)

500

0.75 (0.16)

473

0.76 (0.02)

255

0.76 (0.08)

505

0.76 (0.09)

230

0.77 (0.03)

408

0.77 (0.04)

66

0.78 (0.07)

51

0.78 (0.09)

58

0.78 (0.11)

42
206

0.78 (0.15)
0.79 (0.04)

468

0.8 (0.03)

280

0.8 (0.08)

73
264

0.8 (0.09)
0.8 (0.11)

420

0.81 (0.04)

265

0.81 (0.09)

279

0.82 (0.07)

95
459

0.82 (0.08)
0.82 (0.09)

260

0.82 (0.1)

579

0.82 (0.13)

247

0.82 (0.15)

257

0.83 (0.04)

214

0.83 (0.06)

367

0.83 (0.09)

269

0.83 (0.11)

160

222

0.84 (0.03)

418

0.84 (0.06)

268

0.84 (0.13)

72
204

0.85 (0.03)
0.85 (0.04)

133
244

0.85 (0.05)
0.85 (0.05)

188

0.85 (0.06)

350

0.85 (0.06)

575

0.85 (0.06)

275

0.85 (0.07)

276

0.85 (0.1)

135
343

0.85 (0.12)
0.85 (0.13)

55
475

0.85 (0.15)
0.85 (0.23)

368

0.86 (0.01)

64
251

0.86 (0.03)
0.86 (0.04)

458

0.86 (0.04)

249

0.86 (0.1)

128
256

0.86 (0.11)
0.86 (0.11)

250

0.87 (0.03)

445

0.87 (0.03)

65
211

0.87 (0.05)
0.87 (0.05)

364

0.87 (0.05)

46
196

0.87 (0.06)
0.87 (0.09)

277

0.87 (0.09)

37
353

0.87 (0.12)
0.87 (0.12)

203

0.88 (0.03)

68
210

0.88 (0.04)
0.88 (0.05)

155

0.88 (0.06)

109
456

0.88 (0.1)
0.88 (0.1)

499

0.88 (0.1)

271

0.88 (0.12)

267

0.88 (0.13)

161

96
344

0.88 (0.14)
0.89 (0.04)

386

0.89 (0.04)

112

0.89 (0.05)

144

0.89 (0.05)

132

0.89 (0.06)

117

0.89 (0.08)

104
282

0.89 (0.09)
0.89 (0.1)

261

0.89 (0.12)

120

0.89 (0.15)

27
416

0.89 (0.16)
0.9 (0.04)

252

0.9 (0.06)

221

0.9 (0.07)

451

0.9 (0.07)

568

0.9 (0.07)

69

0.9 (0.08)

154
182

0.9 (0.08)
0.9 (0.08)

520

0.9 (0.08)

75
583

0.9 (0.09)
0.9 (0.09)

23

0.9 (0.1)

103
452

0.9 (0.1)
0.91 (0.03)

471

0.91 (0.03)

131
490

0.91 (0.05)
0.91 (0.06)

513

0.91 (0.08)

83
281

0.91 (0.09)
0.91 (0.09)

465

0.91 (0.09)

338

0.91 (0.1)

374

0.91 (0.11)

248

0.91 (0.12)

278

0.91 (0.13)

585

0.92 (0.03)

62
576

0.92 (0.04)
0.92 (0.04)

136
461

0.92 (0.06)
0.92 (0.06)

162

127
243

0.92 (0.08)
0.92 (0.08)

354

0.92 (0.09)

94
453

0.92 (0.1)
0.92 (0.1)

40
258

0.92 (0.12)
0.92 (0.13)

184

0.93 (0.03)

119

0.93 (0.04)

121

0.93 (0.04)

54

0.93 (0.05)

84
320

0.93 (0.05)
0.93 (0.05)

466

0.93 (0.07)

246

0.93 (0.08)

125
272

0.93 (0.09)
0.93 (0.1)

147

0.93 (0.11)

108

0.93 (0.13)

63
460

0.93 (0.14)
0.94 (0.03)

241

0.94 (0.04)

476

0.94 (0.04)

81
406

0.94 (0.05)
0.94 (0.05)

336

0.94 (0.06)

337

0.94 (0.06)

202

0.94 (0.07)

328

0.94 (0.07)

329

0.94 (0.08)

345

0.94 (0.08)

274

0.94 (0.15)

266

0.95 (0.02)

430

0.95 (0.02)

464

0.95 (0.02)

191

0.95 (0.04)

262

0.95 (0.04)

508

0.95 (0.05)

139

0.95 (0.06)

152
463

0.95 (0.06)
0.95 (0.06)

580

0.95 (0.06)

163

283

0.95 (0.09)

366

0.95 (0.09)

521

0.95 (0.09)

115
284

0.95 (0.12)
0.95 (0.14)

331

0.96 (0.02)

36
362

0.96 (0.03)
0.96 (0.03)

435

0.96 (0.03)

291

0.96 (0.04)

309

0.96 (0.05)

410

0.96 (0.05)

43

0.96 (0.09)

100
474

0.96 (0.1)
0.96 (0.1)

511

0.96 (0.1)

126
439

0.96 (0.11)
0.96 (0.11)

470

0.96 (0.12)

32
304

0.96 (0.34)
0.97 (0.02)

342

0.97 (0.03)

379

0.97 (0.03)

433

0.97 (0.03)

116
316

0.97 (0.04)
0.97 (0.04)

440

0.97 (0.04)

313

0.97 (0.05)

124

0.97 (0.06)

167
290

0.97 (0.06)
0.97 (0.06)

510

0.97 (0.06)

515

0.97 (0.06)

118
273

0.97 (0.07)
0.97 (0.07)

340

0.97 (0.09)

44

0.97 (0.1)

93

0.97 (0.1)

111

0.97 (0.1)

129
431

0.97 (0.11)
0.97 (0.11)

455

0.97 (0.12)

164

171

0.97 (0.13)

98

0.97 (0.14)

80
481

0.97 (0.15)
0.98 (0.01)

357

0.98 (0.02)

270

0.98 (0.04)

30

0.98 (0.05)

145
187

0.98 (0.05)
0.98 (0.06)

428

0.98 (0.07)

469

0.98 (0.07)

105
446

0.98 (0.09)
0.98 (0.09)

253

0.98 (0.1)

582

0.98 (0.11)

235

0.98 (0.12)

26
380

0.98 (0.26)
0.98 (0.27)

388

0.99 (0.02)

447

0.99 (0.03)

322

0.99 (0.04)

359

0.99 (0.04)

349

0.99 (0.05)

395

0.99 (0.05)

245

0.99 (0.06)

399

0.99 (0.06)

161
432

0.99 (0.08)
0.99 (0.08)

504

0.99 (0.08)

528

0.99 (0.09)

163
180

0.99 (0.1)
0.99 (0.1)

101

0.99 (0.14)

29
391

0.99 (0.17)
1 (0.02)

429

1 (0.03)

86
417

1 (0.05)
1 (0.05)

423

1 (0.05)

443

1 (0.05)

172
346

1 (0.06)
1 (0.06)

165

352

1 (0.06)

527

1 (0.06)

237

1 (0.08)

361

1 (0.1)

480

1 (0.11)

91

1 (0.14)

67

1 (0.19)

22
425

1 (0.22)
1.01 (0.02)

35
383

1.01 (0.03)
1.01 (0.03)

122
228

1.01 (0.04)
1.01 (0.04)

88
472

1.01 (0.05)
1.01 (0.05)

110

1.01 (0.06)

113
351

1.01 (0.06)
1.01 (0.07)

467

1.01 (0.07)

232

1.01 (0.08)

299

1.01 (0.08)

400

1.01 (0.08)

57
448

1.01 (0.13)
1.01 (0.13)

483

1.01 (0.14)

559

1.01 (0.16)

503

1.01 (0.2)

195

1.01 (0.27)

566

1.02 (0.03)

89

1.02 (0.07)

130

1.02 (0.07)

158
424

1.02 (0.07)
1.02 (0.08)

462

1.02 (0.08)

168
560

1.02 (0.09)
1.02 (0.09)

334

1.02 (0.11)

297

1.02 (0.12)

387

1.02 (0.14)

454

1.02 (0.15)

85

1.02 (0.18)

38

1.02 (0.28)

166

369

1.03 (0.01)

183

1.03 (0.04)

114
333

1.03 (0.06)
1.03 (0.06)

60

1.03 (0.07)

151
371

1.03 (0.07)
1.03 (0.07)

50

1.03 (0.08)

53
479

1.03 (0.08)
1.03 (0.08)

522

1.03 (0.08)

478

1.03 (0.09)

584

1.03 (0.09)

21
419

1.03 (0.1)
1.03 (0.13)

61

1.03 (0.15)

170
335

1.03 (0.15)
1.04 (0.08)

339

1.04 (0.09)

536

1.04 (0.09)

138

1.04 (0.12)

137
319

1.04 (0.13)
1.04 (0.13)

363

1.04 (0.14)

375

1.04 (0.16)

97
377

1.04 (0.17)
1.04 (0.22)

519

1.05 (0.01)

77

1.05 (0.04)

166

1.05 (0.06)

82

1.05 (0.08)

162
347

1.05 (0.08)
1.05 (0.08)

537

1.05 (0.08)

76
242

1.05 (0.09)
1.05 (0.1)

174

1.05 (0.11)

239

1.05 (0.13)

254

1.05 (0.13)

25

1.05 (0.15)

39
227

1.05 (0.19)
1.05 (0.27)

167

70
477

1.06 (0.03)
1.06 (0.03)

542

1.06 (0.05)

486

1.06 (0.06)

165
301

1.06 (0.07)
1.06 (0.07)

303

1.06 (0.07)

389

1.06 (0.07)

52
225

1.06 (0.08)
1.06 (0.08)

310

1.06 (0.08)

324

1.06 (0.08)

143
509

1.06 (0.09)
1.06 (0.09)

123
577

1.06 (0.1)
1.06 (0.11)

422

1.06 (0.12)

535

1.06 (0.12)

305

1.06 (0.16)

134
315

1.06 (0.17)
1.06 (0.18)

169
370

1.06 (0.22)
1.07 (0.06)

287

1.07 (0.07)

414

1.07 (0.07)

540

1.07 (0.09)

224

1.07 (0.1)

482

1.07 (0.1)

545

1.07 (0.1)

59
365

1.07 (0.11)
1.07 (0.12)

16

1.07 (0.13)

56
565

1.07 (0.13)
1.07 (0.13)

49
497

1.07 (0.14)
1.07 (0.23)

178

1.07 (0.26)

185

1.07 (0.34)

181

1.08 (0.01)

318

1.08 (0.07)

578

1.08 (0.11)

382

1.08 (0.12)

168

142
581

1.08 (0.13)
1.08 (0.13)

571

1.08 (0.22)

561

1.09 (0.03)

308

1.09 (0.06)

517

1.09 (0.06)

552

1.09 (0.08)

372

1.09 (0.09)

307

1.09 (0.1)

544

1.09 (0.11)

355

1.09 (0.12)

71
193

1.09 (0.13)
1.09 (0.13)

19
492

1.09 (0.17)
1.09 (0.17)

41

1.09 (0.3)

159
294

1.1 (0.03)
1.1 (0.05)

327

1.1 (0.05)

450

1.1 (0.06)

341

1.1 (0.1)

436

1.1 (0.1)

177

1.1 (0.12)

302

1.1 (0.12)

321

1.1 (0.13)

574

1.1 (0.15)

356

1.1 (0.17)

314

1.1 (0.21)

438

1.1 (0.22)

312

1.11 (0.05)

226

1.11 (0.08)

384

1.11 (0.08)

92
213

1.11 (0.09)
1.11 (0.16)

31

1.11 (0.19)

45
295

1.11 (0.21)
1.12 (0.09)

223

1.12 (0.12)

216

1.12 (0.16)

292

1.12 (0.16)

189

1.13 (0.04)

421

1.13 (0.05)

169

140
186

1.13 (0.06)
1.13 (0.07)

153
376

1.13 (0.09)
1.13 (0.1)

541

1.13 (0.1)

326

1.13 (0.11)

496

1.13 (0.11)

157
441

1.13 (0.13)
1.13 (0.16)

317

1.13 (0.24)

512

1.13 (0.29)

526

1.13 (0.32)

148

1.14 (0.07)

102
220

1.14 (0.09)
1.14 (0.17)

298

1.15 (0.08)

434

1.15 (0.13)

286

1.15 (0.15)

192

1.15 (0.19)

141
548

1.15 (0.24)
1.15 (0.24)

300

1.16 (0.04)

289

1.16 (0.07)

546

1.16 (0.09)

518

1.16 (0.19)

28
495

1.16 (0.2)
1.16 (0.23)

209

1.17 (0.06)

506

1.17 (0.08)

449

1.17 (0.14)

514

1.17 (0.15)

234

1.17 (0.16)

573

1.17 (0.17)

415

1.17 (0.18)

558

1.18 (0.04)

555

1.18 (0.08)

563

1.18 (0.08)

516

1.18 (0.09)

524

1.18 (0.09)

381

1.18 (0.13)

231

1.18 (0.15)

373

1.18 (0.2)

170

325

1.18 (0.23)

10
551

1.19 (0.07)
1.19 (0.08)

358

1.19 (0.09)

404

1.19 (0.12)

217

1.19 (0.13)

149
539

1.19 (0.2)
1.19 (0.32)

20
215

1.19 (0.36)
1.2 (0.02)

199

1.2 (0.06)

285

1.2 (0.09)

332

1.2 (0.11)

296

1.2 (0.16)

176

1.2 (0.21)

330

1.21 (0.01)

311

1.21 (0.05)

200

1.21 (0.13)

173

1.21 (0.15)

205

1.21 (0.19)

556

1.21 (0.26)

390

1.21 (0.43)

198

1.22 (0.11)

150
397

1.22 (0.12)
1.22 (0.13)

207

1.22 (0.16)

106

1.22 (0.19)

18
411

1.22 (0.37)
1.23 (0.09)

87
493

1.23 (0.14)
1.23 (0.15)

569

1.24 (0.09)

426

1.24 (0.13)

572

1.24 (0.14)

146
444

1.24 (0.24)
1.25 (0.06)

549

1.25 (0.12)

507

1.25 (0.15)

484

1.25 (0.16)

554

1.25 (0.21)

190

1.25 (0.25)

194

1.26 (0.04)

171

323

1.26 (0.09)

485

1.26 (0.15)

553

1.26 (0.15)

306

1.26 (0.18)

501

1.26 (0.22)

398

1.27 (0.09)

547

1.27 (0.16)

212

1.27 (0.2)

523

1.27 (0.23)

24
401

1.27 (0.49)
1.28 (0.06)

488

1.28 (0.1)

538

1.28 (0.18)

208

1.28 (0.28)

494

1.28 (0.29)

550

1.29 (0.08)

562

1.29 (0.23)

156
405

1.29 (0.29)
1.3 (0.03)

427

1.3 (0.25)

409

1.3 (0.28)

240

1.31 (0.04)

402

1.31 (0.12)

412

1.31 (0.24)

570

1.32 (0.02)

487

1.32 (0.17)

442

1.32 (0.18)

489

1.32 (0.18)

531

1.33 (0.05)

530

1.33 (0.1)

197

1.33 (0.12)

164

1.33 (0.27)

7
394

1.33 (0.33)
1.34 (0.06)

11
392
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